Tri-specific t-cell engagers and methods of use in cancer therapeutics
Patent Information
- Application Number
- PCT/US2024/020005
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-14
- Filing Date
- 2024-03-14
- Publication Date
- 2024-11-07
AI Technical Summary
Current cancer therapies, such as bispecific T cell engagers, require continuous intravenous infusion and have limitations in production and stability, necessitating a longer-lived, simpler production method for antibody-based products in cancer immunotherapy.
Development of synthetic trispecific T cell engagers (TriTEs) with three binding domains, including disease-associated antigen binding domains and immune cell engaging domains, specifically targeting tumor antigens like EGFRvIII and IL13Ra2, and immune cell receptors like CD3, to enhance T cell engagement and cytotoxicity.
TriTEs demonstrate long-term expression and complete tumor clearance in orthotopic glioblastoma multiforme models with a single administration, offering a more efficient and stable treatment option compared to existing therapies.
Smart Images

Figure US2024020005_07112024_PF_FP_ABST
Abstract
Description
TRI-SPECIFIC T-CELL ENGAGERS AND METHODS OF USE IN CANCERTHERAPEUTICSCROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Application No. 63 / 490,182, filed March 14, 2023, which is hereby incorporated by reference herein in its entirety.BACKGROUND OF THE INVENTION
[0002] Blood cancers are prevalent in the US, with blood cancers representing 9.8% of new cancer cases. Immunotherapy has been a game-changer in cancers therapeutics, however, this treatment has several limitations including requirement for repeated administration, more limited stability and cost. A further advance on monoclonal technology is the development of bispecific T cell engagers (BTE or BiTE) which combine the specificity of monoclonal antibodies with the cytotoxic potential of T cells. BTEs have shown promising results in leukemia clinical trials (Viardot et al., 2016, Blood, 127(11): 1410-6; Goebeler et al., 2016, J Clin Oncol, 34(10): 1104-11), however, this therapy has a limited applicability because it requires continuous intravenous infusion for 4-8 weeks per cycle (Zhu et al., 2016, Clin Pharmacokinet, 55(10): 1271-88) and can have limitations for its production. A longer-lived simpler production method for antibodybased products would likely be an important new tool for cancer immunotherapy.
[0003] Thus there is need in the art for longer-lived, simpler production, antibodybased products for cancer immunotherapy. The current invention satisfies this need.SUMMARY OF THE INVENTION
[0004] In one embodiment, the invention relates to a synthetic trispecific T cell engager (TriTE), wherein the synthetic trispecific immune cell engager comprises three binding domains, wherein at least one binding domain is a disease-associated antigen binding domain and at least one binding domain immune cell engaging domain.
[0005] In one embodiment, the TriTE comprises two disease-associated antigen binding domains. In one embodiment, at least one disease-associated antigen binding domains is specific for binding a tumor antigen. In one embodiment, the tumor antigen is EGFRvIII or IL13Ra2. In one embodiment, at least one antigen binding domain targets EGFRvIII, and further wherein at least one antigen binding domain targets IL13Ra2.
[0006] In one embodiment, the immune cell engaging domain targets at least one T cell specific receptor molecule. In one embodiment, the immune cell engaging domain targets CD3, the T cell receptor (TCR), CD28, CD16, NKG2D, 0x40, 4-1BB, CD2, CD5, CD40, FcgRs, FceRs, FcaRs or CD95. In one embodiment, the immuine cell engaging domain targets CD3.
[0007] In one embodiment, the TriTE comprises two antigen binding domains and one immune cell engaging domain.
[0008] In one embodiment, the TriTE comprises an antigen binding domain that targets EGFRvIII, an antigen binding domain that targets IL13Ra2, and an immune cell engaging domain that targets CD3.
[0009] In one embodiment, the TriTE comprises an amino acid sequence having at least about 90% identity over an entire length of the amino acid sequence to SEQ ID NON, SEQ ID NO:4 or SEQ ID NO:6, wherein the variation is outside of the CDR sequences of SEQ ID NON, SEQ ID NO:4 or SEQ ID NO: 6.
[0010] In one embodiment, the TriTE comprises a fragment of an amino acid sequence having at least about 90% identity over at least 65% of SEQ ID NO:2, SEQ ID NON or SEQ ID NO:6, wherein the fragment comprises at least the CDR sequences of SEQ ID NO:2, SEQ ID NON or SEQ ID NON. In one embodiment, the TriTE comprises an amino acid sequence of SEQ ID NON, SEQ ID NON or SEQ ID NON.
[0011] In one embodiment, the TriTE comprises a fragment of SEQ ID NON, SEQ ID NON or SEQ ID NON lacking the IgE leader sequence.
[0012] In one embodiment, the invention relates to a nucleic acid molecule encoding a TriTE comprising two disease-associated antigen binding domains. In one embodiment, at least one disease-associated antigen binding domains is specific for binding a tumor antigen. In one embodiment, the tumor antigen is EGFRvIII or IL13Ra2. In oneembodiment, at least one antigen binding domain targets EGFRvIII, and further wherein at least one antigen binding domain targets IL13Ra2.
[0013] In one embodiment, the nucleic acid molecule is an RNA molecule. In one embodiment, the nucleic acid molecule is a DNA molecule.
[0014] In one embodiment, the nucleic acid molecule encodes a TriTE comprising two disease-associated antigen binding domains. In one embodiment, at least one disease- associated antigen binding domains is specific for binding a tumor antigen. In one embodiment, the tumor antigen is EGFRvIII or IL13Ra2. In one embodiment, at least one antigen binding domain targets EGFRvIII. and further wherein at least one antigen binding domain targets IL13Ra2. In one embodiment, the immune cell engaging domain targets at least one T cell specific receptor molecule. In one embodiment, the immune cell engaging domain targets CD3, the T cell receptor (TCR), CD28, CD16, NKG2D, 0x40, 4-1BB, CD2. CD5. CD40, FcgRs, FceRs, FcaRs or CD95. In one embodiment, the immuine cell engaging domain targets CD3.
[0015] In one embodiment, the nucleic acid molecule encodes a TriTE comprising two antigen binding domains and one immune cell engaging domain.
[0016] In one embodiment, the nucleic acid molecule encodes a TriTE comprising an antigen binding domain that targets EGFRvIII, an antigen binding domain that targets IL13Ra2, and an immune cell engaging domain that targets CD3.
[0017] In one embodiment, the nucleic acid molecule encodes a TriTE comprising an amino acid sequence having at least about 90% identity over an entire length of the amino acid sequence to SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6, wherein the variation is outside of the CDR sequences of SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO: 6.
[0018] In one embodiment, the nucleic acid molecule encodes a TriTE comprising a fragment of an amino acid sequence having at least about 90% identity over at least 65% of SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6, wherein the fragment comprises at least the CDR sequences of SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6. In one embodiment, the TriTE comprises an amino acid sequence of SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO: 6.
[0019] In one embodiment, the nucleic acid molecule encodes a TriTE comprising a fragment of SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6 lacking the IgE leader sequence.
[0020] In one embodiment, the nucleic acid molecule comprises a nucleotide sequence having at least about 90% identity over an entire length of the nucleic acid sequence to SEQ ID NO: 1, SEQ ID NO:3 or SEQ ID NO:5, wherein the variation is outside of the CDR coding sequences of SEQ ID NO: 1. SEQ ID NO:3 or SEQ ID NO:5. In one embodiment, the nucleic acid molecule comprises a fragment of a nucleotide sequence having at least about 90% identity over at least 65% of the nucleic acid sequence to SEQ ID NO: 1, SEQ ID NO:3 or SEQ ID NO:5, wherein the fragment comprises at lest the CDR coding sequences of SEQ ID NO: 1, SEQ ID NO:3 or SEQ ID NO:5. In one embodiment, the nucleic acid molecule comprises anucleotide sequence of SEQ ID NO: 1, SEQ ID NO:3 or SEQ ID NO:5
[0021] In one embodiment, the nucleic acid molecule comprises an expression vector.
[0022] In one embodiment, the invention provides a composition comprising a TriTE, wherein the TriTE comprises three binding domains, wherein at least one binding domain is a disease-associated antigen binding domain and at least one binding domain immune cell engaging domain.
[0023] In one embodiment, the composition further comprises a pharmaceutically acceptable excipient, an adjuvant, or a combination thereof.
[0024] In one embodiment, the invention provides a composition comprising a nucleic acid molecule encoding a TriTE, wherein the TriTE comprises three binding domains, wherein at least one binding domain is a disease-associated antigen binding domain and at least one binding domain immune cell engaging domain. In one embodiment, the composition further comprises a pharmaceutically acceptable excipient, an adjuvant, or a combination thereof.
[0025] In one embodiment, the composition comprises a delivery vehicle comprising or encapsulating the nucleic acid molecule nucleic acid molecule encoding a TriTE, wherein the TriTE comprises three binding domains, wherein at least one bindingdomain is a disease-associated antigen binding domain and at least one binding domain immune cell engaging domain.
[0026] In one embodiment, the delivery vehicle is a lipid nanoparticle.
[0027] In one embodiment, the invention provides a method of preventing or treating cancer in a subject, the method comprising administering to the subject a TriTE, or a composition comprising a nucleic acid molecule encoding a TriTE, wherein the TriTE comprises three binding domains, wherein at least one binding domain is a disease- associated antigen binding domain and at least one binding domain immune cell engaging domain.
[0028] In one embodiment, the invention provides a method of preventing or treating glioblastoma multiforme in a subject, the method comprising administering to the subject a TriTE, , or a composition comprising a TriTE, wherein the TriTE comprises three binding domains, wherein at least one binding domain is a disease-associated antigen binding domain and at least one binding domain immune cell engaging domain. In one embodiment, the TriTE comprises an antigen binding domain that targets EGFRvllI. an antigen binding domain that targets IL13Ra2, and an immune cell engaging domain that targets CD3.
[0029] In one embodiment, the invention provides a method of preventing or treating cancer in a subject, the method comprising administering to the subject a nucleic acid molecule encoding a TriTE, , or a composition comprising a nucleic acid molecule encoding a TriTE, wherein the TriTE comprises three binding domains, wherein at least one binding domain is a disease-associated antigen binding domain and at least one binding domain immune cell engaging domain.
[0030] In one embodiment, the invention provides a method of preventing or treating glioblastoma multiforme in a subject, the method comprising administering to the subject a nucleic acid molecule encoding a TriTE. or a composition comprising a nucleic acid molecule encoding a TriTE, wherein the TriTE comprises three binding domains, wherein at least one binding domain is a disease-associated antigen binding domain and at least one binding domain immune cell engaging domain. In one embodiment, the TriTE comprises an antigen binding domain that targets EGFRvllI, an antigen binding domain that targets IL13Ra2, and an immune cell engaging domain that targets CD3.BRIEF DESCRIPTION OF THE DRAWINGS
[0031] The following detailed description of various embodiments of the invention will be better understood when read in conjunction with the appended drawings. For the purpose of illustrating the invention, illustrative embodiments are show n in the drawings. It should be understood, however, that the invention is not limited to the precise arrangements and instrumentalities of the embodiments shown in the drawings.
[0032] Figure 1A through Figure ID demonstrate the design and in vitro expression of DTriTE. Figure 1A depicts a schematic of a DNA-encoded tri -specific T cell engager (DTriTE) that consists of three single-chain variable fragments (scFv) targeting lL13Ra2, CD3, and EGFRvIII that is embedded in pVAXl expression vector along with human IgE leader sequence. Figure IB depicts a schematic illustrating that DTriTE can engage T cells into cytotoxicity against IL 13Ra2 -expressing and EGFRvIII-expressing tumor cells. Figure 1C depicts a schematic illustrating that DTriTE is treated by IM injection followed by electroporation which results in in vivo expression in the system. Figure ID depicts a representative western blot demonstrating that DTriTE has larger molecular weight of 78 kDa compared to conventional bispecific antibodies, which is shown in Western Blotting using lysate samples of expi293F cells transfected with DTriTE.
[0033] Figure 2 depicts representative experimental results demonstrating the binding activities of DTriTE. DTriTE shows on-cell binding activities to EGFRvIII- expressing U87 cells, IL13Ra2-expressing U251 cells and CD3 on primary human T cells. DTriTE was added to each target cells, probed by anti -human F(ab’)2 antibody, and analyzed by flow cytometry. pVAX empty vector was used as vehicle control. EGFRvIII- targeting bispecific (EGFRvIII-DBTE), IL13Ra2 -targeting bispecific (IL13Ra2-DBTE), and FSHR-targeting DBTE (FSHR-DBTE) were used as antibody controls.
[0034] Figure 3A and Figure 3B depict representative experimental results demonstrating T cell-mediated cytotoxicity of DTriTE against EGFRvIII-expressing and IL13Ra2-expressing GBM cells. Figure 3A depicts representative graphs plotting DTriTE induced T cell-mediated cytotoxicity against heterogeneous mixture of U87vIII and U251 cells. Target cells were grown on a culture plate for 20 hours. Antibodies were added at lOng / ml along with primary human T cells (E:T = 10: 1). Cell viabilities were monitored using xCelligence eSight system. Cell indices w ere normalized at addition of antibodies andeffector cells. Figure 3B depicts representative microscopic images of heterogeneous mixture tumor cells (U87vIII and U251) at 0-hour and 48-hour time points after adding antibodies and effector cells.
[0035] Figure 4 depicts representative results demonstrating that DTriTE shows longterm expression in vivo. DTriTE was injected in TA muscle ofNSG mice followed by electroporation (EP). Sera were collected longitudinally and were added to tumor killing assay against mixture of U87vIII and U251 cells. DTriTE shows long-term expression after a single treatment.
[0036] Figure 5A through Figure 5D depict representative experimental results demonstrating that DTriTE clears heterogeneous tumors in an orthotopic GBM challenge after a single administration. Figure 5A depicts a scheme of orthotopic GBM challenge. Figure 5B depicts a representative survival curve of the challenged mice. Figure 5C depicts representative graphs plotting the brain tumor burden of each mouse measured by IVIS imaging system. Figure 5D depicts representative bioluminescent IVIS images of challenged mice. Cross indicates that the mouse reached the endpoint.DETAILED DESCRIPTION
[0037] The present invention relates to compositions comprising a tri-specific T cell engaging (TriTE) molelcules, fragments thereof, variants thereof, combinations thereof and nucleic acid molecules encoding the same. In one embodiment, the composition is a nucleic acid molecule encoding a tri-specific T cell engager.
[0038] The present invention relates to compositions comprising a tri-specific binding molecules including a tri-specific T cell engaging binding molecule fragments thereof, variants thereof, combinations thereof and nucleic acid molecules encoding the same. In various embodiments, the TriTE comprises at least three antigen binding domains. In one embodiment, at least one of the three antigen binding domains of the TriTE is specific for binding a target antigen and recruiting a T cell to the target antigen. In one embodiment, at least one target antigen is a tumor antigen. In one embodiment, the tumor antigen is EGFRVIII. In one embodiment, the target antigen is IL13Ra2. In one embodiment, the TriTE comprises at least two antigen binding domains specific for bindingto tumor antigens. In one embodiment, at least one of the tumor antigens is EGFRvIII. In one embodiment, at least one of the tumor antigens is IL13Ra2. In one embodiment, the TriTE comprises a first tumor antigen binding domaing specific for binding to EGFRvIII and a second tumor antigen binding domaing specific for binding to IL13Ra2.
[0039] In various embodiments, the TriTE comprises at least one immune cell engaging domain. In various embodiments, the TriTE comprises an immune cell engaging domain that binds to a T cell specific receptor molecule. In one embodiment, the T cell specific receptor molecule is a T cell surface antigen. In one embodiment, the T cell specific receptor molecule is one of CD3, TCR, CD28, CD16, NKG2D, 0x40, 4-1BB, CD2, CD5, CD40, FcgRs, FceRs, FcaRs and CD95. In one embodiment, the T cell specific receptor molecule is CD3.
[0040] In one embodiment, the TriTE comprises at least one antigen binding domain and at least one immune cell engaging domain. In one embodiment, the TriTE comprises two antigen binding domains and one immune cell engaging domain. In one embodiment, the TriTE comprises a first tumor antigen binding domaing specific for binding to EGFRvIII, a second tumor antigen binding domaing specific for binding to IL13Ra2. and an immune cell engaging domain specific for binding to CD3.. In one embodiment, the composition of the invention provides complete tumor clearance in an orthotopic challenge model of heterogeneous glioblastoma multiforme (GBM).
[0041] In some embodiments, the invention provides nucleic acid molecules encoding the TriTE of the invention. In some embodiments, the nucleic acid molecule is a DNA molecule. In some embodiments, the nucleic acid molecule is an RNA molecule.
[0042] Therefore, in one embodiment, the invention provides compositions comprising at least one TriTE, or at least one nucleic acid molecule encoding the TriTE, and methods for use in treating or preventing cancer or a disease or disorder associated with cancer in a subject.Definitions
[0043] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In case of conflict, the present document, including definitions, will control. Preferred methods andmaterials are described below, although methods and materials similar or equivalent to those described herein can be used in practice or testing of the present invention. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. The materials, methods, and examples disclosed herein are illustrative only and not intended to be limiting.
[0044] The terms “comprise(s),” “include(s),’' “having,"’ “has,” “can,” “contain(s),” and variants thereof, as used herein, are intended to be open-ended transitional phrases, terms, or words that do not preclude the possibility of additional acts or structures. The singular forms “a,” “and” and “the” include plural references unless the context clearly dictates otherwise. The present disclosure also contemplates other embodiments “comprising,” “consisting of’ and “consisting essentially of,” the embodiments or elements presented herein, whether explicitly set forth or not.
[0045] “Antibody” may mean an antibody of classes IgG. IgM, IgA, IgD or IgE, or fragments, fragments or derivatives thereof, including Fab, F(ab')2, Fd, and single chain antibodies, and derivatives thereof. The antibody may be an antibody isolated from the serum sample of mammal, a polyclonal antibody, affinity purified antibody, or mixtures thereof which exhibits sufficient binding specificity to a desired epitope or a sequence derived therefrom.
[0046] “Antibody fragment” or “fragment of an antibody” as used interchangeably herein refers to a portion of an intact antibody comprising the antigen-binding site or variable region. The portion does not include the constant heavy chain domains (i.e. CH2, CH3, or CH4, depending on the antibody isotype) of the Fc region of the intact antibody. Examples of antibody fragments include, but are not limited to. Fab fragments. Fab' fragments, Fab'-SH fragments, F(ab')2 fragments, Fd fragments, Fv fragments, diabodies, single-chain Fv (scFv) molecules, single-chain polypeptides containing only one light chain variable domain, single-chain polypeptides containing the three CDRs of the light-chain variable domain, single-chain polypeptides containing only one heavy chain variable region, and single-chain polypeptides containing the three CDRs of the heavy chain variable region.
[0047] “Antigen’" refers to proteins that have the ability to generate an immune response in a host. An antigen may be recognized and bound by an antibody. An antigen may originate from within the body or from the external environment.
[0048] “Coding sequence” or “encoding nucleic acid” as used herein may mean refers to the nucleic acid (RNA or DNA molecule) that comprise a nucleotide sequence which encodes an antibody as set forth herein. The coding sequence may further include initiation and termination signals operably linked to regulatory elements including a promoter and poly adenylation signal capable of directing expression in the cells of an individual or mammal to whom the nucleic acid is administered. The coding sequence may further include sequences that encode signal peptides.
[0049] “Complement” or “complementary” as used herein may mean a nucleic acid may mean Watson-Crick (e.g., A-T / U and C-G) or Hoogsteen base pairing between nucleotides or nucleotide analogs of nucleic acid molecules.
[0050] “Endogenous antibody” as used herein may refer to an antibody that is generated in a subject that is administered an effective dose of an antigen for induction of a humoral immune response.
[0051] “Feedback mechanism” as used herein may refer to a process performed by either software or hardware (or firmware), which process receives and compares the impedance of the desired tissue (before, during, and / or after the delivery7of pulse of energy ) with a present value, preferably current, and adjusts the pulse of energy delivered to achieve the preset value. A feedback mechanism may be performed by an analog closed loop circuit.
[0052] “Fragment” may mean a polypeptide fragment of an antibody that is function, i.e., can bind to desired target and have the same intended effect as a full length antibody. A fragment of an antibody may be 100% identical to the full length except missing at least one amino acid from the N and / or C terminal, in each case with or without signal peptides and / or a methionine at position 1. Fragments may comprise 20% or more, 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more. 95% or more, 96% or more, 97% or more, 98% or more. 99% or more percent of the length of theparticular full length antibody, excluding any heterologous signal peptide added. The fragment may comprise a fragment of a polypeptide that is 95% or more, 96% or more, 97% or more, 98% or more or 99% or more identical to the antibody and additionally comprise an N terminal methionine or heterologous signal peptide which is not included when calculating percent identity’. Fragments may further comprise an N terminal methionine and / or a signal peptide such as an immunoglobulin signal peptide, for example an IgE or IgG signal peptide. The N terminal methionine and / or signal peptide may be linked to a fragment of an antibody.
[0053] A fragment of a nucleic acid sequence that encodes an antibody may be 100% identical to the full length except missing at least one nucleotide from the 5' and / or 3' end, in each case with or without sequences encoding signal peptides and / or a methionine at position 1. Fragments may comprise 20% or more, 25% or more, 30% or more, 35% or more, 40% or more, 45% or more, 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more. 97% or more, 98% or more, 99% or more percent of the length of the particular full length coding sequence, excluding any heterologous signal peptide added. The fragment may comprise a fragment that encode a polypeptide that is 95% or more, 96% or more, 97% or more, 98% or more or 99% or more identical to the antibody and additionally optionally comprise sequence encoding an N terminal methionine or heterologous signal peptide which is not included when calculating percent identity. Fragments may further comprise coding sequences for an N terminal methionine and / or a signal peptide such as an immunoglobulin signal peptide, for example an IgE or IgG signal peptide. The coding sequence encoding the N terminal methionine and / or signal peptide may be linked to a fragment of coding sequence.
[0054] “Genetic construct'’ as used herein refers to the DNA or RNA molecules that comprise a nucleotide sequence which encodes a protein, such as an antibody. The coding sequence includes initiation and termination signals operably linked to regulatory’ elements including a promoter and polyadenylation signal capable of directing expression in the cells of the individual to whom the nucleic acid molecule is administered. As used herein, the term "expressible form" refers to gene constructs that contain the necessary regulatoryelements operable linked to a coding sequence that encodes a protein such that when present in the cell of the individual, the coding sequence will be expressed.
[0055] “Identical” or “identity7’ as used herein in the context of two or more nucleic acids or polypeptide sequences, may mean that the sequences have a specified percentage of residues that are the same over a specified region. The percentage may be calculated by optimally aligning the two sequences, comparing the two sequences over the specified region, determining the number of positions at which the identical residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the specified region, and multiplying the result by 100 to yield the percentage of sequence identity. In cases where the two sequences are of different lengths or the alignment produces one or more staggered ends and the specified region of comparison includes only a single sequence, the residues of single sequence are included in the denominator but not the numerator of the calculation. When comparing DNA and RNA, thymine (T) and uracil (U) may be considered equivalent. Identity may be performed manually or by using a computer sequence algorithm such as BLAST or BLAST 2.0.
[0056] “Immune response” as used herein may mean the activation of a host’s immune system, e.g., that of a mammal, in response to the introduction of one or more nucleic acids and / or peptides. The immune response can be in the form of a cellular or humoral response, or both.
[0057] “Nucleic acid” or “oligonucleotide” or “polynucleotide” as used herein may mean at least two nucleotides covalently linked together. The depiction of a single strand also defines the sequence of the complementary strand. Thus, a nucleic acid also encompasses the complementary strand of a depicted single strand. Many variants of a nucleic acid may be used for the same purpose as a given nucleic acid. Thus, a nucleic acid also encompasses substantially identical nucleic acids and complements thereof. A single strand provides a probe that may hybridize to a target sequence under stringent hybridization conditions. Thus, a nucleic acid also encompasses a probe that hybridizes under stringent hybridization conditions.
[0058] Nucleic acids may be single stranded or double stranded, or may contain portions of both double stranded and single stranded sequence. The nucleic acid may beDNA, both genomic and cDNA. RNA, or a hybrid, where the nucleic acid may contain combinations of deoxyribo- and ribo-nucleotides, and combinations of bases including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine and isoguanine. Nucleic acids may be obtained by chemical synthesis methods or by recombinant methods.
[0059] “Operably linked” as used herein may mean that expression of a gene is under the control of a promoter with which it is spatially connected. A promoter may be positioned 5' (upstream) or 3' (downstream) of a gene under its control. The distance between the promoter and a gene may be approximately the same as the distance between that promoter and the gene it controls in the gene from which the promoter is derived. As is known in the art, variation in this distance may be accommodated without loss of promoter function.
[0060] A “peptide.” “protein,” or “polypeptide” as used herein can mean a linked sequence of amino acids and can be natural, synthetic, or a modification or combination of natural and synthetic.
[0061] “Promoter” as used herein may mean a synthetic or naturally-derived molecule which is capable of conferring, activating or enhancing expression of a nucleic acid in a cell. A promoter may comprise one or more specific transcriptional regulatory sequences to further enhance expression and / or to alter the spatial expression and / or temporal expression of same. A promoter may also comprise distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription. A promoter may be derived from sources including viral, bacterial, fungal, plants, insects, and animals. A promoter may regulate the expression of a gene component constitutively, or differentially with respect to cell, the tissue or organ in which expression occurs or, with respect to the developmental stage at which expression occurs, or in response to external stimuli such as physiological stresses, pathogens, metal ions, or inducing agents. Representative examples of promoters include the bacteriophage T7 promoter, bacteriophage T3 promoter. SP6 promoter, lac operator-promoter, tac promoter. SV40 late promoter, SV40 early promoter, RSV-LTR promoter, CMV IE promoter, SV40 early promoter or SV 40 late promoter and the CMV IE promoter.
[0062] “Signal peptide7’ and “leader sequence” are used interchangeably herein and refer to an amino acid sequence that can be linked at the amino terminus of a protein set forth herein. Signal peptides / leader sequences typically direct localization of a protein. Signal peptides / leader sequences used herein preferably facilitate secretion of the protein from the cell in which it is produced. Signal peptides / leader sequences are often cleaved from the remainder of the protein, often referred to as the mature protein, upon secretion from the cell. Signal peptides / leader sequences are linked at the N terminus of the protein.
[0063] “Stringent hybridization conditions” as used herein may mean conditions under which a first nucleic acid sequence (e.g., probe) will hybridize to a second nucleic acid sequence (e.g., target), such as in a complex mixture of nucleic acids. Stringent conditions are sequence dependent and will be different in different circumstances. Stringent conditions may be selected to be about 5-10°C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength pH. The Tm may be the temperature (under defined ionic strength, pH, and nucleic concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at Tm, 50% of the probes are occupied at equilibrium). Stringent conditions may be those in which the salt concentration is less than about 1.0 M sodium ion, such as about 0.01-1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g., about 10- 50 nucleotides) and at least about 60°C for long probes (e.g., greater than about 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide. For selective or specific hybridization, a positive signal may be at least 2 to 10 times background hybridization. Exemplary stringent hybridization conditions include the following: 50% formamide, 5x SSC, and 1% SDS. incubating at 42°C, or. 5x SSC, 1% SDS, incubating at 65°C. with wash in 0.2x SSC, and 0.1% SDS at 65°C.
[0064] “Subject” and “patient” as used herein interchangeably refers to any vertebrate, including, but not limited to, a mammal (e.g., cow, pig, camel, llama, horse, goat, rabbit, sheep, hamsters, guinea pig, cat, dog, rat, and mouse, a non-human primate (for example, a monkey, such as a cynomolgous or rhesus monkey, chimpanzee, etc) and ahuman). In some embodiments, the subject may be a human or a non-human. The subject or patient may be undergoing other forms of treatment.
[0065] “Substantially complementary’7as used herein may mean that a first sequence is at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the complement of a second sequence over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50. 55. 60. 65. 70, 75, 80, 85, 90, 95, 100 or more nucleotides or amino acids, or that the two sequences hybridize under stringent hybridization conditions.
[0066] ’‘Substantially identical” as used herein may mean that a first and second sequence are at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% over a region of 1, 2, 3, 4, 5. 6, 7, 8. 9, 10, 11. 12. 13. 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30. 35. 40. 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100 or more nucleotides or amino acids, or with respect to nucleic acids, if the first sequence is substantially complementary to the complement of the second sequence.
[0067] “Synthetic antibody” as used herein refers to an antibody that is encoded by the recombinant nucleic acid sequence described herein and is generated in a subject.
[0068] “Treatment” or “treating,” as used herein can mean protecting of a subject from a disease through means of preventing, suppressing, repressing, or completely eliminating the disease. Preventing the disease involves administering an antibody of the present invention to a subject prior to onset of the disease. Suppressing the disease involves administering a antibody of the present invention to a subject after induction of the disease but before its clinical appearance. Repressing the disease involves administering an antibody of the present invention to a subject after clinical appearance of the disease.
[0069] “Variant” used herein with respect to a nucleic acid may mean (i) a portion or fragment of a referenced nucleotide sequence; (ii) the complement of a referenced nucleotide sequence or portion thereof; (iii) a nucleic acid that is substantially identical to a referenced nucleic acid or the complement thereof; or (iv) a nucleic acid that hybridizes under stringent conditions to the referenced nucleic acid, complement thereof, or a sequences substantially identical thereto.
[0070] “Variant” with respect to a peptide or polypeptide that differs in amino acid sequence by the insertion, deletion, or conservative substitution of amino acids, but retain at least one biological activity. Variant may also mean a protein with an amino acid sequence that is substantially identical to a referenced protein with an amino acid sequence that retains at least one biological activity. A conservative substitution of an amino acid, i.e., replacing an amino acid with a different amino acid of similar properties (e.g., hydrophilicity, degree and distribution of charged regions) is recognized in the art as typically involving a minor change. These minor changes can be identified, in part, by considering the hydropathic index of amino acids, as understood in the art. Kyte et al., J. Mol. Biol. 157: 105-132 (1982). The hydropathic index of an amino acid is based on a consideration of its hydrophobicity and charge. It is known in the art that amino acids of similar hydropathic indexes can be substituted and still retain protein function. In one aspect, amino acids having hydropathic indexes of ±2 are substituted. The hydrophilicity' of amino acids can also be used to reveal substitutions that would result in proteins retaining biological function. A consideration of the hydrophilicity of amino acids in the context of a peptide permits calculation of the greatest local average hydrophilicity of that peptide, a useful measure that has been reported to correlate well with antigenicity and immunogenicity. U.S. Patent No. 4,554,101, incorporated fully herein by reference. Substitution of amino acids having similar hydrophilicity values can result in peptides retaining biological activity, for example immunogenicity’, as is understood in the art. Substitutions may be performed with amino acids having hydrophilicity values within ±2 of each other. Both the hyrophobicity index and the hydrophilicity value of amino acids are influenced by the particular side chain of that amino acid. Consistent with that observation, amino acid substitutions that are compatible with biological function are understood to depend on the relative similarity of the amino acids, and particularly the side chains of those amino acids, as revealed by the hydrophobicity7, hydrophilicity, charge, size, and other properties.
[0071] A variant may be a nucleic acid sequence that is substantially identical over the full length of the full gene sequence or a fragment thereof. The nucleic acid sequence may be 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical over the full length of the gene sequence or a fragment thereof. A variant may be an amino acid sequence that issubstantially identical over the full length of the amino acid sequence or fragment thereof. The amino acid sequence may be 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical over the full length of the amino acid sequence or a fragment thereof.
[0072] “Vector” as used herein may mean a nucleic acid sequence containing an origin of replication. A vector may be a plasmid, bacteriophage, bacterial artificial chromosome or yeast artificial chromosome. A vector may be a DNA or RNA vector. A vector may be either a self-replicating extrachromosomal vector or a vector which integrates into a host genome.
[0073] For the recitation of numeric ranges herein, each intervening number there between with the same degree of precision is explicitly contemplated. For example, for the range of 6-9, the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0-7.0, the number 6.0, 6.1, 6.2, 6.3, 6.4, 6.5. 6.6, 6.7, 6.8, 6.9. and 7.0 are explicitly contemplated.Compositions
[0074] In one embodiment, the present invention relates to compositions comprising a tri-specific immune cell engager or trispecific T cell engager, a fragment thereof, a variant thereof, or a combination thereof. The compositions, when administered to a subject in need thereof, can result in the generation of a synthetic trispecific immune cell engager in the subject. In some embodiments, the composition of the invention is encoded by a nucleic acid molecue (e.g., DNA or mRNA). Therefore, in some embodiments, the invention relates to nucleic acid molecules encoding a tri-specific immune cell engager or tri specific T cell engager.
[0075] In one embodiment, the tri-specific immune cell engager or trispecific T cell engager comprises at least one antigen binding domain, and at least one immune cell engaging domain. In one embodiment, the immune cell engaging domain is specific for an antigen expressed on the surface of an immune cell. Immune cells include, but are not limited to T cells, antigen presenting cells, NK cells, neutrophils and macrophages.
[0076] In various embodiments, the immune cell engaging domain comprises a nucleotide sequence encoding an antibody, a fragment thereof, or a variant thereof specificfor binding to a immune cell specific receptor molecule. In one embodiment, the immune cell specific receptor molecule is a T cell surface antigen. In one embodiment, the T cell specific receptor molecule is one of CD3, TCR, CD28, CD16, NKG2D, 0x40, 4-1BB, CD2, CD5, CD40, FcgRs, FceRs, FcaRs and CD95.
[0077] In various embodiments, the TriTE comprises at least one antigen binding domain. In various embodiments, the antigen binding domain comprises an antibody, a fragment thereof (e.g., an scFv fragment), or a variant thereof specific for binding to an antigen. In one embodiment, the antigen is a tumor antigen. In one embodiment, the tumor antigen is EGFRvIII. In one embodiment, the tumor antigen is IL13Ra2. In one embodiment, the TriTE comprises two antigen binding domains. In one embodiment, the two antigen binding domains of the TriTE is specific for binding two target antigens. In one embodiment, one target antigen is a tumor antigen. In one embodiment, two target antigens are tumor antigens. In one embodiment, the tumor antigen is EGFRvIII. In one embodiment, the tumor antigen is IL13Ra2. In one embodiment, the two tumor antigens are EGFRvIII and IL13Ra2.
[0078] In one embodiment, the TriTE comprises at least one antigen binding domain and at least one immune cell engaging domain. In one embodiment, the TriTE comprises two antigen binding domains and one immune cell engaging domain. In one embodiment, the TriTE targets EGFRvIII, IL13Ra2, and CD3.
[0079] In one embodiment, the TriTE comprises the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6 or a fragment or variant thereof.
[0080] In some embodiments, the invention provides nucleic acid molecules encoding the TriTE. In some embodiments, the nucleic acid molecule is a DNA molecule. In some embodiments, the nucleic acid molecule is an RNA molecule. In one embodiment, the nucleic acid molecule encodes a TriTE comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6 or a fragment or variant thereof. In some embodiment, the TriTE is encoded by a nucleotide sequence comprising the nucleic acid sequence of SEQ ID NO: 1, SEQ ID NO:3, or SEQ ID NO:5 or a fragment or variant thereof.
[0081] In certain embodiments, the composition can treat, prevent, and or / protect against a disease or disorder associated with EGFRvIII and IL13Ra2 expression.
[0082] The composition of the present invention can have features required of effective compositions such as being safe so that the composition does not cause illness or death; being protective against illness; and providing ease of administration, few side effects, biological stability and low cost per dose.Antibody
[0083] In some embodiments, the invention relates to a recombinant nucleic acid sequence encoding an tri-specific binding molecule, a fragment thereof, a variant thereof, or a combination thereof. The tri-specific binding molecule can bind or react with at least one, at least two or at least three antigens, as described in more detail below. In some embodiments, the binding molecule is a tri-specific binding molecule comprising at least three binding domains, a fragment thereof, or a variant thereof. In some embodiments, the binding molecule is a trispecific T cell engager (TriTE), comprising at least two antigen binding domains and at least one immune cell engaging domain.
[0084] In some embodiments, each antigen binding domain / T cell engaging domain may comprise a heavy chain and a light chain complementarity determining region (“CDR”) set, respectively interposed between a heavy chain and a light chain framework C‘FRT?) set which provide support to the CDRs and define the spatial relationship of the CDRs relative to each other. The CDR set may contain three hypervariable regions of a heavy or light chain V region. Proceeding from the N-terminus of a heavy or light chain, these regions are denoted as “CDR1,” “CDR2,” and “CDR3,” respectively. An antigenbinding site, therefore, may include six CDRs, comprising the CDR set from each of a heavy and a light chain V region.
[0085] The proteolytic enzyme papain preferentially cleaves IgG molecules to yield several fragments, two of which (the F(ab) fragments) each comprise a covalent heterodimer that includes an intact antigen-binding site. The enzyme pepsin is able to cleave IgG molecules to provide several fragments, including the F(ab’)2 fragment, which comprises both antigen-binding sites. Accordingly, the antibody can be the Fab or F(ab')2. The Fab can include the heavy chain polypeptide and the light chain polypeptide. The heavy chain polypeptide of the Fab can include the VH region and the CHI region. The light chain of the Fab can include the VL region and CL region.
[0086] The antibody can be an immunoglobulin (Ig). The Ig can be, for example, IgA, IgM, IgD, IgE, and IgG. The immunoglobulin can include the heavy chain polypeptide and the light chain polypeptide. The heavy chain polypeptide of the immunoglobulin can include a VH region, a CHI region, a hinge region, a CH2 region, and a CH3 region. The light chain polypeptide of the immunoglobulin can include a VL region and CL region.
[0087] The antibody can be a polyclonal or monoclonal antibody. The antibody can be a chimeric antibody, a single chain antibody, an affinity matured antibody, a human antibody, a humanized antibody, or a fully human antibody. The humanized antibody can be an antibody from a non-human species that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and framework regions from a human immunoglobulin molecule.
[0088] The antibody can be a trispecific antibody as described below in more detail. The antibody can be a bifunctional antibody as also described below in more detail.
[0089] The antibody can be generated in the subject upon administration of the composition to the subject. The antibody may have a half-life within the subject. In some embodiments, the antibody may be modified to extend or shorten its half-life within the subject. Such modifications are described below in more detail.Heavy Chain Polypeptide
[0090] The recombinant nucleic acid sequence construct can include a heterologous nucleic acid encoding at least one heavy chain polypeptide, a fragment thereof a variant thereof, or a combination thereof. The heavy chain polypeptide can include a variable heavy chain (VH) region and / or at least one constant heavy chain (CH) region. The at least one constant heavy chain region can include a constant heavy chain region 1 (CHI), a constant heavy chain region 2 (CH2), and a constant heavy chain region 3 (CH3), and / or a hinge region.
[0091] In some embodiments, the heavy chain polypeptide can include a VH region and a CHI region. In other embodiments, the heavy chain polypeptide can include a VH region, a CHI region, a hinge region, a CH2 region, and a CH3 region.
[0092] The heavy chain polypeptide can include a complementarity determining region (“CDR”) set. The CDR set can contain three hypervariable regions of the VH region. Proceeding from N-terminus of the heavy chain polypeptide, these CDRs are denoted “CDR1,” “CDR2,” and “CDR3,” respectively. CDR1, CDR2, and CDR3 of the heavy chain polypeptide can contribute to binding or recognition of the antigen.Light Chain Polypeptide
[0093] The recombinant nucleic acid sequence construct can include a heterologous nucleic acid sequence encoding at least one light chain polypeptide, a fragment thereof, a variant thereof, or a combination thereof. The light chain polypeptide can include a variable light chain (VL) region and / or a constant light chain (CL) region.
[0094] The light chain polypeptide can include a complementarity determining region (“CDR’’) set. The CDR set can contain three hypervariable regions of the VL region. Proceeding from N-terminus of the light chain polypeptide, these CDRs are denoted “CDR1,” “CDR2.” and “CDR3,” respectively. CDRL CDR2. and CDR3 of the light chain polypeptide can contribute to binding or recognition of the antigen.Protease Cleavage Site
[0095] The recombinant nucleic acid sequence construct can include the heterologous nucleic acid sequence encoding the protease cleavage site. The protease cleavage site can be recognized by a protease or peptidase. The protease can be an endopeptidase or endoprotease, for example, but not limited to, furin, elastase, HtrA, calpain, trypsin, chymotrypsin, trypsin, and pepsin. The protease can be furin. In other embodiments, the protease can be a serine protease, a threonine protease, cysteine protease, aspartate protease, metalloprotease, glutamic acid protease, or any protease that cleaves an internal peptide bond (i.e., does not cleave the N-terminal or C-terminal peptide bond).
[0096] The protease cleavage site can include one or more amino acid sequences that promote or increase the efficiency of cleavage. The one or more amino acid sequences can promote or increase the efficiency of forming or generating discrete polypeptides. The one or more amino acids sequences can include a 2A peptide sequence.Linker Sequence
[0097] The recombinant nucleic acid sequence construct can include one or more linker sequences. The linker sequence can spatially separate or link the one or more components described herein. In other embodiments, the linker sequence can encode an amino acid sequence that spatially separates or links two or more polypeptides. In one embodiment, the linker sequence is a G4S linker sequence. In some embodiments, the recombinant nucleic acid sequence construct can include linker sequences between each of the linked antigen binding domains and immune cell binding domain.Leader Sequence
[0098] The recombinant nucleic acid sequence construct can include one or more leader sequences. The leader sequence can encode a signal peptide. The signal peptide can be an immunoglobulin (Ig) signal peptide, for example, but not limited to, an IgG signal peptide and a IgE signal peptide. In one embodiment, the TriTE lacks a leader sequence.ScFv Antibody
[0099] In one embodiment, the binding molecule of the invention comprises multiple linked scFv antibody fragments. In one embodiment, scFv relates to a Fab fragment without the CHI and CL regions. Thus, in one embodiment, the scFv relates to a Fab fragment comprising the VH and VL. In one embodiment, the scFv comprises a linker between VH and VL. In one embodiment, the scFv relates to a Fab fragment comprising the VL and VH. In one embodiment, the scFv comprises a linker between VL and VH. In one embodiment, the scFv fragment is an ScFv-Fc. In one embodiment, the scFv-Fc fragment comprises the VH, VL and the CH2 and CH3 regions. In one embodiment, the scFv-Fc fragment comprises a linker between VH and VL. In one embodiment, the ScFv fragment of the invention has modified expression, stability, half-life, antigen binding, heavy chain - light chain pairing, tissue penetration or a combination thereof as compared to a parental antibody.
[0100] In one embodiment, the scFv incorporated into a TriTE of the invention has at least 1.1 fold, at least 1.2 fold, fold, at least 1.3 fold, at least 1.4 fold, at least 1.5 fold, at least 1.6 fold, at least 1.7 fold, at least 1.8 fold, at least 1.9 fold, at least 2 fold, at least 2.1fold, at least 2.2 fold, at least 2.3 fold, at least 2.4 fold, at least 2.5 fold, at least 2.6 fold, at least 2.7 fold, at least 2.8 fold, at least 2.9 fold, at least 3 fold, at least 3.5 fold, at least 4 fold, at least 4.5 fold, at least 5 fold, at least5.5 fold, at least 6 fold, at least 6.5 fold, at least 7 fold, at least 7.5 fold, at least 8 fold, at least 8.5 fold, at least 9 fold, at least 9.5 fold, at leastlO fold, at least 20 fold, at least 30 fold, at least 40 fold, at least 50 fold or greater than 50 fold higher expression than the parental antibody.
[0101] In one embodiment, the scFv fragment incorporated into a TriTE of the invention has at least 1.1 fold, at least 1.2 fold, fold, at least 1.3 fold, at least 1.4 fold, at least 1.5 fold, at least 1.6 fold, at least 1.7 fold, at least 1.8 fold, at least 1.9 fold, at least 2 fold, at least 2. 1 fold, at least 2.2 fold, at least 2.3 fold, at least 2.4 fold, at least 2.5 fold, at least 2.6 fold, at least 2.7 fold, at least 2.8 fold, at least 2.9 fold, at least 3 fold, at least 3.5 fold, at least 4 fold, at least 4.5 fold, at least 5 fold, at least5.5 fold, at least 6 fold, at least6.5 fold, at least 7 fold, at least 7.5 fold, at least 8 fold, at least 8.5 fold, at least 9 fold, at least 9.5 fold, at leastlO fold, at least 20 fold, at least 30 fold, at least 40 fold, at least 50 fold or greater than 50 fold higher antigen binding than the parental antibody.
[0102] In one embodiment, the scFv fragment incorporated into a TriTE of the invention has at least 1.1 fold, at least 1.2 fold, fold, at least 1.3 fold, at least 1.4 fold, at least 1.5 fold, at least 1.6 fold, at least 1.7 fold, at least 1.8 fold, at least 1.9 fold, at least 2 fold, at least 2. 1 fold, at least 2.2 fold, at least 2.3 fold, at least 2.4 fold, at least 2.5 fold, at least 2.6 fold, at least 2.7 fold, at least 2.8 fold, at least 2.9 fold, at least 3 fold, at least 3.5 fold, at least 4 fold, at least 4.5 fold, at least 5 fold, at least5.5 fold, at least 6 fold, at least6.5 fold, at least 7 fold, at least 7.5 fold, at least 8 fold, at least 8.5 fold, at least 9 fold, at least 9.5 fold, at leastl 0 fold, at least 20 fold, at least 30 fold, at least 40 fold, at least 50 fold or greater than 50 fold longer half-life than the parental antibody.
[0103] In one embodiment, the scFv fragment incorporated into a TriTE of the invention has at least 1.1 fold, at least 1.2 fold, fold, at least 1.3 fold, at least 1.4 fold, at least 1.5 fold, at least 1.6 fold, at least 1.7 fold, at least 1.8 fold, at least 1.9 fold, at least 2 fold, at least 2. 1 fold, at least 2.2 fold, at least 2.3 fold, at least 2.4 fold, at least 2.5 fold, at least 2.6 fold, at least 2.7 fold, at least 2.8 fold, at least 2.9 fold, at least 3 fold, at least 3.5 fold, at least 4 fold, at least 4.5 fold, at least 5 fold, at least5.5 fold, at least 6 fold, at least6.5 fold, at least 7 fold, at least 7.5 fold, at least 8 fold, at least 8.5 fold, at least 9 fold, atleast 9.5 fold, at leastlO fold, at least 20 fold, at least 30 fold, at least 40 fold, at least 50 fold or greater than 50 fold higher stability than the parental antibody.
[0104] In one embodiment, the scFv fragment incorporated into a TriTE of the invention has at least 1. 1 fold, at least 1.2 fold, fold, at least 1.3 fold, at least 1.4 fold, at least 1.5 fold, at least 1.6 fold, at least 1.7 fold, at least 1.8 fold, at least 1.9 fold, at least 2 fold, at least 2. 1 fold, at least 2.2 fold, at least 2.3 fold, at least 2.4 fold, at least 2.5 fold, at least 2.6 fold, at least 2.7 fold, at least 2.8 fold, at least 2.9 fold, at least 3 fold, at least 3.5 fold, at least 4 fold, at least 4.5 fold, at least 5 fold, at least5.5 fold, at least 6 fold, at least 6.5 fold, at least 7 fold, at least 7.5 fold, at least 8 fold, at least 8.5 fold, at least 9 fold, at least 9.5 fold, at leastlO fold, at least 20 fold, at least 30 fold, at least 40 fold, at least 50 fold or greater than 50 fold greater tissue penetration than the parental antibody.
[0105] In one embodiment, the scFv fragment incorporated into a TriTE of the invention has at least 1.1 fold, at least 1.2 fold, fold, at least 1.3 fold, at least 1.4 fold, at least 1.5 fold, at least 1.6 fold, at least 1.7 fold, at least 1.8 fold, at least 1.9 fold, at least 2 fold, at least 2. 1 fold, at least 2.2 fold, at least 2.3 fold, at least 2.4 fold, at least 2.5 fold, at least 2.6 fold, at least 2.7 fold, at least 2.8 fold, at least 2.9 fold, at least 3 fold, at least 3.5 fold, at least 4 fold, at least 4.5 fold, at least 5 fold, at leasts.5 fold, at least 6 fold, at least 6.5 fold, at least 7 fold, at least 7.5 fold, at least 8 fold, at least 8.5 fold, at least 9 fold, at least 9.5 fold, at leastlO fold, at least 20 fold, at least 30 fold, at least 40 fold, at least 50 fold or greater than 50 fold greater heavy chain - light chain pairing than the parental antibody.Trispecific T cell Engager
[0106] As described above, the binding molecule of the invention can be a trispecific T cell engager (TriTE), a fragment thereof, a variant thereof, or a combination thereof. The antigen targeting domain of the TriTE can bind or react with the antigen, which is described in more detail below.
[0107] The antigen targeting domain of the TriTE may comprise an antibody, a fragment thereof, a variant thereof, or a combination thereof. Each antigen targeting domain of the TriTE may comprise a heavy chain and a light chain complementarity determining region (“CDR”) set, respectively interposed between a heavy chain and a light chainframework C FR”) set which provide support to the CDRs and define the spatial relationship of the CDRs relative to each other. The CDR set may contain three hypervariable regions of a heavy or light chain V region. Proceeding from the N-terminus of a heavy or light chain, these regions are denoted as “CDR1,’" “CDR2,’' and ' CDRS. " respectively. An antigen-binding domain, therefore, may include six CDRs, comprising the CDR set from each of a heavy and a light chain V region.
[0108] In one embodiment, a nucleotide sequence encoding an EGFRvIII, IL13Ra2, CD3 TriTE comprises at least one nucleotide sequence of SEQ ID NO: 1, SEQ ID NO:3, or SEQ ID NO:5 or a fragment or variant thereof. In one embodiment, the fragment of SEQ ID NO:1, SEQ ID NO:3, or SEQ ID NO:5 encodes a binding fragment of a TriTE of the invention, and comprises at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, at least seventeen, or all eighteen CDR coding sequences of SEQ ID NO: 1, SEQ ID NO:3, or SEQ ID NO:5, encoding at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, at least ten, at least eleven, at least twelve, at least thirteen, at least fourteen, at least fifteen, at least sixteen, at least seventeen, or all eighteen CDR sequences of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6. In some embodiments, the fragment of SEQ ID NO: 1. SEQ ID NO:3, or SEQ ID NO:5 encodes a binding fragment of a TriTE of the invention comprising at least three CDR sequences of SEQ ID NO:2. SEQ ID NO:4, or SEQ ID NO:6. In some embodiments, the fragment of SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:3, or SEQ ID NO:5encodes a binding fragment of a TriTE of the invention comprising at least six CDR sequences of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:4, or SEQ ID NO:6.
[0109] The proteolytic enzyme papain preferentially cleaves IgG molecules to yield several fragments, two of which (the F(ab) fragments) each comprise a covalent heterodimer that includes an intact antigen-binding site. The enzyme pepsin is able to cleave IgG molecules to provide several fragments, including the F(ab')2 fragment, which comprises both antigen-binding sites. Accordingly, the antigen targeting domain of the TriTE can be the Fab or F(ab’)2. The Fab can include the heavy chain polypeptide and the light chain polypeptide. The heavy chain polypeptide of the Fab can include the VH region and the CHI region. The light chain of the Fab can include the VL region and CL region.
[0110] The antigen targeting domain of the TriTE can be an immunoglobulin (Ig). The Ig can be, for example, IgA, IgM, IgD, IgE, and IgG. The immunoglobulin can include the heavy chain polypeptide and the light chain polypeptide. The heavy chain polypeptide of the immunoglobulin can include a VH region, a CHI region, a hinge region, a CH2 region, and a CH3 region. The light chain polypeptide of the immunoglobulin can include a VL region and CL region.
[0111] The antigen targeting domain of the TriTE can be a polyclonal or monoclonal antibody. The antibody can be a chimeric antibody, a single chain antibody, an affinity matured antibody, a human antibody, a humanized antibody, or a fully human antibody. The humanized antibody can be an antibody from a non-human species that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and framework regions from a human immunoglobulin molecule.
[0112] In some embodiments, the invention includes nucleic acid molecules (e.g., DNA or mRNA) encoding the TriTE.
[0113] In one embodiment, at least one of the antigen binding domain and the immune cell engaging domain of the TriTE of the invention is an scFv antibody fragment as described in detail above.
[0114] In one embodiment, the TriTE comprises a first antigen binding domain linked to a second antigen binding domain linked to the immune cell engaging domain.
[0115] In one embodiment, the TriTE comprises a first antigen binding domain linked to the immune cell engaging domain linked to a second antigen binding domain linked.
[0116] In one embodiment, the TriTE comprises an immune cell engaging domain linked to a first antigen binding domain which is linked a second antigen binding domain.Antigen
[0117] In one embodiment, the TriTE molecule is directed to an antigen or fragment or variant thereof. The antigen can be a nucleic acid sequence, an amino acid sequence, a polysaccharide or a combination thereof. The nucleic acid sequence can be DNA, RNA.cDN A. a variant thereof, a fragment thereof, or a combination thereof. The amino acid sequence can be a protein, a peptide, a variant thereof, a fragment thereof, or a combination thereof. The polysaccharide can be a nucleic acid encoded polysaccharide.
[0118] In some embodiments, at least one antigen is a disease-associated antigen. In some embodiments, at least one antigen is a tumor antigen. The antigen can be associated with increased risk of cancer development or progression. In one embodiment, the antigen is EGFRvIII. In one embodiment, the antigen is IL13Ra.
[0119] In one embodiment, a synthetic trispecific immune cell engager or T cell engager of the invention targets two or more antigens. In one embodiment, at least one antigen is a tumor antigen. In one embodiment, at least one antigen is EGFRvIII. In one embodiment, at least one antigen is IL13Ra2. In one embodiment, the two antigens are EGFRvIII and IL13Ra2.Tumor antigen
[0120] The t pe of tumor antigen referred to in the invention may be a tumorspecific antigen (TSA) or a tumor-associated antigen (TAA). A TSA is unique to tumor cells and does not occur on other cells in the body. A TAA antigen is not unique to a tumor cell and instead is also expressed on a normal cell under conditions that fail to induce a state of immunologic tolerance to the antigen. The expression of the antigen on the tumor may occur under conditions that enable the immune system to respond to the antigen. TAAs may be antigens that are expressed on normal cells during fetal development when the immune system is immature and unable to respond or they may be antigens that are normally present at extremely low levels on normal cells but which are expressed at much higher levels on tumor cells.
[0121] The antigens discussed herein are merely included by way of example. The list is not intended to be exclusive and further examples will be readily apparent to those of skill in the art.
[0122] Tumor antigens are proteins that are produced by tumor cells that elicit an immune response, particularly T-cell mediated immune responses. The selection of the antigen binding moiety of the invention will depend on the particular type of cancer to be treated. Tumor antigens are well known in the art and include, for example, a glioma-associated antigen, carcinoembryonic antigen (CEA), [3-human chorionic gonadotropin, alphafetoprotein (AFP), lectin-reactive AFP, thyroglobulin, RAGE-1, MN-CA IX, human telomerase reverse transcriptase, RU1, RU2 (AS), intestinal carboxyl esterase, mut hsp70-2, M-CSF, prostase, prostate-specific antigen (PSA), PAP, NY-ESO-1, LAGE-la, p53, prostein, PSMA, Her2. survivin and telomerase, prostate-carcinoma tumor antigen- 1 (PCTA-1). MAGE, ELF2M. neutrophil elastase, ephrinB2, CD22, insulin grow th factor (IGF)-I, IGF-II, IGF-I receptor and mesothelin.
[0123] Illustrative examples of a tumor associated surface antigen are CD 10, CD 19, CD20, CD22, CD33, CD123, B-cell maturation antigen (BCMA), Fms-like tyrosine kinase 3 (FLT-3, CD135), chondroitin sulfate proteoglycan 4 (CSPG4, melanoma-associated chondroitin sulfate proteoglycan), Epidermal growth factor receptor (EGFR). EIer2, Her3, IGFR, CD133, IL3R, fibroblast activating protein (FAP), CDCP1, Derlinl, Tenascin, frizzled 1-10, the vascular antigens VEGFR2 (KDR / FLK1), VEGFR3 (FLT4, CD309), PDGFR-a (CD140a), PDGFR-.beta. (CD140b) Endoglin, CLEC14, Teml-8, and Tie2. Further examples may include A33, CAMPATH- 1 (CDw52), Carcinoembryonic antigen (CEA). Carboanhydrase IX (MN / CA IX), CD21, CD25, CD30. CD34, CD37, CD44v6, CD45, CD133, de2-7 EGFR, EGFRvIII, EpCAM, Ep-CAM, Folate-binding protein, G250, Fms-like tyrosine kinase 3 (FLT-3, CD135), follicle stimulating hormone receptor (FSHR), c-Kit (CD117), CSF1R (CD115), HLA-DR, IGFR, IL-2 receptor, IL3R, IL13Ra2, MCSP (Melanoma-associated cell surface chondroitin sulphate proteoglycane), Muc-1, Prostatespecific membrane antigen (PSMA), Prostate stem cell antigen (PSCA), Prostate specific antigen (PSA), and TAG-72. Examples of antigens expressed on the extracellular matrix of tumors are tenascin and the fibroblast activating protein (FAP).
[0124] In one embodiment, the tumor antigen is a hormone or fragment thereof which can be used to target a specific receptor. Examples include, but are not limited to, FSH hormone, LH hormone. TSH hormone or fragments thereof.
[0125] Non-limiting examples of TSA or TAA antigens include the following: Differentiation antigens such as MART-l / MelanA (MART-I), gplOO (Pmel 17), tyrosinase, TRP-1, TRP-2 and tumor-specific multilineage antigens such as MAGE-1 , MAGE-3, BAGE, GAGE-1, GAGE-2, pl5; overexpressed embry onic antigens such as CEA; overexpressed oncogenes and mutated tumor-suppressor genes such as p53, Ras, HER-2 / neu; unique tumor antigens resulting from chromosomal translocations; such as BCR- ABL, E2A-PRL, H4-RET, IGH-IGK, MYL-RAR; and viral antigens, such as the Epstein Barr virus antigens EBVA and the human papillomavirus (HPV) antigens E6 and E7. Other large, protein-based antigens include TSP-180, MAGE-4, MAGE-5, MAGE-6, RAGE, NY- ESO, pl85erbB2, pl80erbB-3, c-met, nm-23Hl, PSA, TAG-72, CA 19-9, CA 72-4, CAM 17.1. NuMa, K-ras, beta-Catemn, CDK4, Mum-1, p 15. p 16. 43-9F, 5T4, 791Tgp72, alpha- fetoprotein, beta-HCG, BCA225, BTAA, CA 125, CA 15-3\CA 27.29\BCAA, CA 195, CA 242, CA-50, CAM43, CD68\P1, CO-029, FGF-5, G250, Ga733\EpCAM, HTgp-175, M344, MA-50. MG7-Ag, M0V18, NB / 70K, NY-CO-1, RCAS1, SDCCAG16, TA- 90\Mac-2 binding protein\cyclophilin C-associated protein. TAAL6, TAG72, TLP. and TPS.Recombinant Nucleic Acid Sequence
[0126] As described above, the composition can comprise a recombinant nucleic acid sequence. The recombinant nucleic acid sequence can encode the trispecific T cell engager or a fragment thereof, a variant thereof, or a combination thereof.
[0127] The recombinant nucleic acid sequence can be a heterologous nucleic acid sequence. The recombinant nucleic acid sequence can include at least one heterologous nucleic acid sequence or one or more heterologous nucleic acid sequences.
[0128] In one embodiment, a nucleotide sequence encoding a trispecific T cell engager comprises a nucleotide sequence of SEQ ID NO: 1, SEQ ID NO:3, SEQ ID NO:5 or a fragment or variant thereof. In one embodiment, the nucleotide sequence encodes a trispecific T cell engager having the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO: 6 or a fragment or variant thereof.
[0129] The recombinant nucleic acid sequence can be an optimized nucleic acid sequence. Such optimization can increase or alter the immunogenicity of the antibody. Optimization can also improve transcription and / or translation. Optimization can include one or more of the following: low GC content leader sequence to increase transcription; mRNA stability7and codon optimization; addition of a kozak sequence (e.g., GCC ACC) for increased translation; addition of an immunoglobulin (Ig) leader sequence encoding a signal peptide; and eliminating to the extent possible cis-acting sequence motifs (i.e., internal TATA boxes).
[0130] The recombinant nucleic acid sequence can include one or more recombinant nucleic acid sequence constructs. The recombinant nucleic acid sequence construct can include one or more components, which are described in more detail below.Promoter
[0131] The recombinant nucleic acid sequence construct can include one or more promoters. The one or more promoters may be any promoter that is capable of driving gene expression and regulating gene expression. Such a promoter is a cis-acting sequence element required for transcription via a DNA dependent RNA polymerase. Selection of the promoter used to direct gene expression depends on the particular application. The promoter may be positioned about the same distance from the transcription start in the recombinant nucleic acid sequence construct as it is from the transcription start site in its natural setting. However, variation in this distance may be accommodated without loss of promoter function.
[0132] The promoter may be operably linked to the heterologous nucleic acid sequence encoding the heavy chain polypeptide and / or light chain polypeptide. The promoter may be a promoter shown effective for expression in eukaryotic cells. The promoter operably linked to the coding sequence may be a CMV promoter, a promoter from simian virus 40 (SV40), such as SV40 early promoter and SV40 later promoter, a mouse mammary tumor virus (MMTV) promoter, a human immunodeficiency virus (HIV) promoter such as the bovine immunodeficiency virus (B1V) long terminal repeat (LTR) promoter, a Moloney virus promoter, an avian leukosis virus (ALV) promoter, a cytomegalovirus (CMV) promoter such as the CMV immediate early promoter, Epstein Barr virus (EBV) promoter, or a Rous sarcoma virus (RSV) promoter. The promoter may also be a promoter from a human gene such as human actin, human myosin, human hemoglobin, human muscle creatine, human polyhedrin, or human metalothionein.
[0133] The promoter can be a constitutive promoter or an inducible promoter, which initiates transcription only when the host cell is exposed to some particular external stimulus. In the case of a multicellular organism, the promoter can also be specific to a particular tissue or organ or stage of development. The promoter may also be a tissue specific promoter, such as a muscle or skin specific promoter, natural or synthetic.Examples of such promoters are described in US patent application publication no. US20040175727, the contents of which are incorporated herein in its entirety.
[0134] The promoter can be associated with an enhancer. The enhancer can be located upstream of the coding sequence. The enhancer may be human actin, human myosin, human hemoglobin, human muscle creatine or a viral enhancer such as one from CMV, FMDV. RSV or EBV. Polynucleotide function enhances are described in U.S. Patent Nos. 5,593,972, 5,962,428, and W094 / 016737, the contents of each are fully incorporated by reference.Transcription Termination Region
[0135] The recombinant nucleic acid sequence construct can include one or more transcription termination regions. The transcription termination region can be downstream of the coding sequence to provide for efficient termination. The transcription termination region can be obtained from the same gene as the promoter described above or can be obtained from one or more different genes.Initiation Codon
[0136] The recombinant nucleic acid sequence construct can include one or more initiation codons. The initiation codon can be located upstream of the coding sequence. The initiation codon can be in frame with the coding sequence. The initiation codon can be associated with one or more signals required for efficient translation initiation, for example, but not limited to, a ribosome binding site.Termination Codon
[0137] The recombinant nucleic acid sequence construct can include one or more termination or stop codons. The termination codon can be dow nstream of the coding sequence. The termination codon can be in frame with the coding sequence. The termination codon can be associated with one or more signals required for efficient translation termination.Polyadenylation Signal
[0138] The recombinant nucleic acid sequence construct can include one or more polyadenylation signals. The polyadenylation signal can include one or more signals required for efficient poly adenylation of the transcript. The poly adenylation signal can be positioned downstream of the coding sequence. The polyadenylation signal may be a SV40 polyadenylation signal, LTR polyadenylation signal, bovine grow th hormone (bGH) polyadenylation signal, human growth hormone (hGH) polyadenylation signal, or human f>- globin polyadenylation signal. The SV40 polyadenylation signal may be a polyadenylation signal from a pCEP4 plasmid (Invitrogen, San Diego, CA).Vector
[0139] The recombinant nucleic acid sequence construct described above can be placed in one or more vectors. The one or more vectors can contain an origin of replication. The one or more vectors can be a plasmid, bacteriophage, bacterial artificial chromosome or yeast artificial chromosome. The one or more vectors can be either a selfreplication extra chromosomal vector, or a vector which integrates into a host genome.
[0140] The one or more vectors can be a heterologous expression construct, which is generally a plasmid that is used to introduce a specific gene into a target cell. Once the expression vector is inside the cell, the heavy chain polypeptide and / or light chain polypeptide that are encoded by the recombinant nucleic acid sequence construct is produced by the cellular-transcription and translation machinery ribosomal complexes. The one or more vectors can express large amounts of stable messenger RNA, and therefore proteins.Expression Vector
[0141] The one or more vectors can be a circular plasmid or a linear nucleic acid. The circular plasmid and linear nucleic acid are capable of directing expression of a particular nucleotide sequence in an appropriate subject cell. The one or more vectors comprising the recombinant nucleic acid sequence construct may be chimeric, meaning that at least one of its components is heterologous with respect to at least one of its other components.Plasmid
[0142] The one or more vectors can be a plasmid. The plasmid may be useful for transfecting cells with the recombinant nucleic acid sequence construct. The plasmid may be useful for introducing the recombinant nucleic acid sequence construct into the subject. The plasmid may also comprise a regulatory sequence, which may be well suited for gene expression in a cell into which the plasmid is administered.
[0143] The plasmid may also comprise a mammalian origin of replication in order to maintain the plasmid extrachromosomally and produce multiple copies of the plasmid in a cell. The plasmid may be pVAXl, pCEP4 or pREP4 from Invitrogen (San Diego, CA), which may comprise the Epstein Barr virus origin of replication and nuclear antigen EBNA-1 coding region, which may produce high copy episomal replication without integration. The backbone of the plasmid may be pAV0242. The plasmid may be a replication defective adenovirus ty pe 5 (Ad5) plasmid.
[0144] The plasmid may be pSE420 (Invitrogen, San Diego, Calif.), which may be used for protein production in Escherichia coli (E.coli). The plasmid may also be p YES2 (Invitrogen, San Diego, Calif), which may be used for protein production in Saccharomyces cerevisiae strains of yeast. The plasmid may also be of the MAXBAC™ complete baculovirus expression system (Invitrogen, San Diego, Calif.), which may be used for protein production in insect cells. The plasmid may also be pcDNAI or pcDNA3 (Invitrogen, San Diego, Calif.), which may be used for protein production in mammalian cells such as Chinese hamster ovary (CEIO) cells.RNA
[0145] In one embodiment, the nucleic acid is an RNA molecule. In one embodiment, the RNA molecule is transcribed from a DNA sequence. Accordingly, in one embodiment, the invention provides an RNA molecule encoding one or more of the synthetic antibodies of the invention. The RNA may be plus-stranded. Accordingly, in some embodiments, the RNA molecule can be translated by cells without needing any intervening replication steps such as reverse transcription. A RNA molecule useful with the invention may have a 5' cap (e.g. a 7-methylguanosine). This cap can enhance in vivo translation of the RNA. The 5' nucleotide of a RNA molecule useful with the invention may have a 5' triphosphate group. In a capped RNA this may be linked to a 7-methylguanosinevia a 5'-to-5' bridge. A RNA molecule may have a 3' poly-A tail. It may also include a poly-A polymerase recognition sequence (e.g. AAUAAA) near its 3' end. A RNA molecule useful with the invention may be single-stranded. A RNA molecule useful with the invention may comprise synthetic RNA. In some embodiments, the RNA molecule is a naked RNA molecule. In one embodiment, the RNA molecule is comprised within a vector.
[0146] In one embodiment, the RNA has 5' and 3' UTRs. In one embodiment, the 5' UTR is between zero and 3000 nucleotides in length. The length of 5' and 3' UTR sequences to be added to the coding region can be altered by different methods, including, but not limited to, designing primers for PCR that anneal to different regions of the UTRs. Using this approach, one of ordinary skill in the art can modify the 5' and 3' UTR lengths required to achieve optimal translation efficiency following transfection of the transcribed RNA.
[0147] The 5' and 3' UTRs can be the naturally occurring, endogenous 5' and 3' UTRs for the gene of interest. Alternatively. UTR sequences that are not endogenous to the gene of interest can be added by incorporating the UTR sequences into the forward and reverse primers or by any other modifications of the template. The use of UTR sequences that are not endogenous to the gene of interest can be useful for modifying the stability and / or translation efficiency of the RNA. For example, it is known that AU-rich elements in 3' UTR sequences can decrease the stability of RNA. Therefore, 3' UTRs can be selected or designed to increase the stability of the transcribed RNA based on properties of UTRs that are well known in the art.
[0148] In one embodiment, the 5' UTR can contain the Kozak sequence of the endogenous gene. Alternatively, when a 5' UTR that is not endogenous to the gene of interest is being added by PCR as described above, a consensus Kozak sequence can be redesigned by adding the 5' UTR sequence. Kozak sequences can increase the efficiency of translation of some RNA transcripts, but does not appear to be required for all RNAs to enable efficient translation. The requirement for Kozak sequences for many RNAs is known in the art. In other embodiments, the 5' UTR can be derived from an RNA virus whose RNA genome is stable in cells. In other embodiments, various nucleotide analogues can be used in the 3' or 5' UTR to impede exonuclease degradation of the RNA.
[0149] In one embodiment, the RNA has both a cap on the 5' end and a 3' poly(A) tail which determine ribosome binding, initiation of translation and stability of RNA in the cell.
[0150] In one embodiment, the RNA is a nucleoside-modified RNA. Nucleoside- modified RNA have particular advantages over non-modified RNA, including for example, increased stability, low or absent innate immunogenicity, and enhanced translation.Circular and Linear Vector
[0151] The one or more vectors may be circular plasmid, which may transform a target cell by integration into the cellular genome or exist extrachromosomally (e.g., autonomous replicating plasmid with an origin of replication). The vector can be pVAX, pcDNA3.0, or provax, or any other expression vector capable of expressing the heavy chain polypeptide and / or light chain polypeptide encoded by the recombinant nucleic acid sequence construct.
[0152] Also provided herein is a linear nucleic acid, or linear expression cassette (“LEC”), that is capable of being efficiently delivered to a subject via electroporation and expressing the heavy chain polypeptide and / or light chain polypeptide encoded by the recombinant nucleic acid sequence construct. The LEC may be any linear DNA devoid of any phosphate backbone. The LEC may not contain any antibiotic resistance genes and / or a phosphate backbone. The LEC may not contain other nucleic acid sequences unrelated to the desired gene expression.
[0153] The LEC may be derived from any plasmid capable of being linearized. The plasmid may be capable of expressing the heavy chain polypeptide and / or light chain polypeptide encoded by the recombinant nucleic acid sequence construct. The plasmid can be pNP (Puerto Rico / 34) or pM2 (New Caledonia / 99). The plasmid may be WLV009, pVAX, pcDNA3.0, or provax, or any other expression vector capable of expressing the heavy chain polypeptide and / or light chain polypeptide encoded by the recombinant nucleic acid sequence construct.
[0154] The LEC can be pcrM2. The LEC can be pcrNP. pcrNP and pcrMR can be derived from pNP (Puerto Rico / 34) and pM2 (New Caledonia / 99), respectively.Methods of Delivery of the Composition
[0155] The present invention also relates to a method of delivering the composition to the subject in need thereof. The method of delivery can include, administering the composition to the subject. In some embodiments, the present invention relates to administration of a trispecific T cell engager targeting at least two antigens, or a nucleic acid molecule encoding the trispecific T cell engager molecule of the invention. In some embodiments, the nucleic acid molecule is a DNA molecule. In some embodiments, the nucleic acid molecule is an RNA molecule. In some embodiments, the nucleic acid molecule is an mRN A molecule.
[0156] The mammal receiving delivery of the composition may be human, primate, non-human primate, cow, cattle, sheep, goat, antelope, bison, water buffalo, bison, bovids, deer, hedgehogs, elephants, llama, alpaca, mice, rats, and chicken.
[0157] The composition may be administered by different routes including orally, parenterally, sublingually, transdermally, rectally, transmucosally, topically, via inhalation, via buccal administration, intrapleurally, intravenous, intraarterial, intraperitoneal, subcutaneous, intramuscular, intranasal intrathecal, and intraarticular or combinations thereof. For veterinary use, the composition may be administered as a suitably acceptable formulation in accordance with normal veterinary practice. The veterinarian can readily determine the dosing regimen and route of administration that is most appropriate for a particular animal. The composition may be administered by traditional syringes, needleless injection devices, "microprojectile bombardment gone guns", or other physical methods such as electroporation (“EP”), “hydrodynamic method”, or ultrasound.Delivery Vehicles
[0158] In one embodiment, the present invention provides a composition comprising a delivery vehicle comprising a TriTE molecule or fragment thereof, or nucleic acid molecule encoding the same, as described herein. In one embodiment, the nucleic acid molecule encoding the TriTE comprises an mRNA molecule. In one embodiment, the nucleic acid molecule encoding the TriTE comprises a DNA molecule.
[0159] Exemplary7delivery' vehicles include, but are not limited to, microspheres, microparticles, nanoparticles, polymerosomes, liposomes, and micelles. For example, insome embodiments, the delivery vehicle is a lipid nanoparticle loaded with a nucleic acid molecule encoding a TriTE of the invention or a fragment thereof. In one embodiment, the nucleic acid molecule encoding the TriTE is an mRNA molecule.
[0160] In some embodiments, the delivery7vehicle provides for controlled release, delayed release, or continual release of its loaded cargo. In some embodiments, the delivery vehicle comprises a targeting moiety that targets the delivery vehicle to a treatment site.
[0161] In certain instances, expressing a protein by delivering the encoding mRNA has many benefits over methods that use protein, plasmid DNA or viral vectors. During mRNA transfection, the coding sequence of the desired protein is the only substance delivered to cells, thus avoiding all the side effects associated with plasmid backbones, viral genes, and viral proteins. More importantly, unlike DNA- and viral-based vectors, the mRNA does not carry the risk of being incorporated into the genome and protein production starts immediately after mRNA delivery. For example, high levels of circulating proteins have been measured within 15 to 30 min of in vivo injection of the encoding mRNA. In certain embodiments, using mRNA rather than the protein also has many advantages. Elalf-lives of proteins in the circulation are often short, thus protein treatment would need frequent dosing, while mRNA provides a template for continuous protein production for several days. Purification of proteins is problematic and they can contain aggregates and other impurities that cause adverse effects (Kromminga and Schellekens, 2005, Ann NY Acad Sci 1050:257-265).
[0162] In order to confirm the presence of the mRNA sequence in the host cell, a variety of assays may be performed. Such assays include, for example, “molecular biological assays well known to those of skill in the art, such as Northern blotting and RT- PCR; “biochemical” assays, such as detecting the presence or absence of a particular peptide, e.g., by immunogenic means (ELISAs and Western blots) or by assays described herein to identify agents falling within the scope of the invention.
[0163] In one embodiment, the immunogenic composition of the invention may comprise a nanoparticle, including but not limited to a lipid nanoparticle (LNP), comprising a TriTE of the invention, or a LNP comprising a nucleic acid encoding a TriTE of the invention. In some embodiments, the composition comprises or encodes all or part of a IL13Ra2 binding molecule of the invention, or an immunogenically functional equivalentthereof. In some embodiments, the composition comprises an mRNA molecule that encodes all or part of a IL13Ra2 binding molecule of the invention.
[0164] In one embodiment, the LNP comprises or encapsulates an RNA molecule encoding at least one amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6, or a fragment or variant thereof. In one embodiment, the LNP comprises or encapsulates a DNA molecule encoding at least one amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:6, or a fragment or variant thereof.
[0015] In one embodiment, the composition further comprises one or more additional immunostimulatory agents. Immunostimulatory' agents include, but are not limited to, an additional antigen or antigen binding molecule, an immunomodulator, or an adjuvant.Method of Treatment
[0166] Also provided herein is a method of treating, protecting against, and / or preventing disease in a subject in need thereof by administration of a tri-specific T cell engager of the invention to the subject. Administration of the composition to the subject can be done using the method of delivery described above.
[0167] In certain embodiments, the invention provides a method of treating protecting against, and / or preventing cancer. In one embodiment, the method treats, protects against, and / or prevents tumor growth. In one embodiment, the method treats, protects against, and / or prevents cancer progression. In one embodiment, the method treats, protects against, and / or prevents cancer metastasis.
[0168] In one embodiment, the invention provides methods for preventing growth of benign tumors, such as, but not limited to, uterine fibroids. The methods comprise administering an effective amount of one or more of the compositions of the invention to a subject diagnosed with a benign tumor.
[0169] Upon generation of the synthetic antibody (e.g., TriTE) in the subject, the synthetic antibody (e.g., TriTE) can bind to or react with the antigen. Such binding can neutralize the antigen, block recognition of the antigen by another molecule, for example, a protein or nucleic acid, and elicit or induce an immune response to the antigen, therebytreating, protecting against, and / or preventing the disease associated with the antigen in the subject.
[0170] The composition dose can be between 1 pg to 10 mg active component / kg body weight / time, and can be 20 pg to 10 mg component / kg body weight / time. The composition can be administered every 1, 2. 3, 4, 5, 6, 7, 8, 9. 10. 11, 12, 13, 14, 15, 16, 17, 18. 19. 20. 21, 22, 23, 24, 25, 26, 27, 28, 29. 30. or 31 days. The number of composition doses for effective treatment can be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.Cancer Therapy
[0171] The invention provides methods of treating or preventing cancer, or of treating and preventing grow th or metastasis of tumors. Related aspects of the invention provide methods of preventing, aiding in the prevention, and / or reducing metastasis of hyperplastic or tumor cells in an individual.
[0172] One aspect of the invention provides a method of inhibiting metastasis in an individual in need thereof, the method comprising administering to the individual an effective amount of a composition of the invention. The invention further provides a method of inhibiting metastasis in an individual in need thereof, the method comprising administering to the individual an effective metastasis-inhibiting amount of any one of the compositions described herein.
[0173] In some embodiments of treating or preventing cancer, or of treating and preventing metastasis of tumors in an individual in need thereof, a second agent is administered to the individual, such as an antineoplastic agent. In some embodiments, the second agent comprises a second metastasis-inhibiting agent, such as a plasminogen antagonist, or an adenosine deaminase antagonist. In other embodiments, the second agent is an angiogenesis inhibiting agent.
[0174] The compositions of the invention can be used to prevent, abate, minimize, control, and / or lessen cancer in humans and animals. The compositions of the invention can also be used to slow the rate of primary tumor growth. The compositions of the invention when administered to a subject in need of treatment can be used to stop the spread of cancer cells. As such, the compositions of the invention can be administered as part of a combination therapy with one or more drugs or other pharmaceutical agents. When used as part of the combination therapy, the decrease in metastasis and reduction in primary tumorgrowth afforded by the compositions of the invention allows for a more effective and efficient use of any pharmaceutical or drug therapy being used to treat the patient. In addition, control of metastasis by the compositions of the invention affords the subject a greater ability- to concentrate the disease in one location.
[0175] In one embodiment, the invention provides methods for preventing metastasis of malignant tumors or other cancerous cells as well as to reduce the rate of tumor growth. The methods comprise administering an effective amount of one or more of the compositions of the invention to a subject diagnosed with a malignant tumor or cancerous cells or to a subject having a tumor or cancerous cells.
[0176] The following are non-limiting examples of cancers that can be treated by the methods and compositions of the invention: Acute Lymphoblastic; Acute Myeloid Leukemia; Adrenocortical Carcinoma; Adrenocortical Carcinoma, Childhood; Appendix Cancer; Basal Cell Carcinoma; Bile Duct Cancer, Extrahepatic; Bladder Cancer; Bone Cancer; Osteosarcoma and Malignant Fibrous Histiocytoma; Brain Stem Glioma, Childhood; Brain Tumor, Adult; Brain Tumor, Brain Stem Glioma, Childhood; Brain Tumor, Central Nervous System Atypical Teratoid / Rhabdoid Tumor, Childhood; Central Nervous System Embryonal Tumors; Cerebellar Astrocytoma; Cerebral Astrocytotna / Malignant Glioma; Craniopharyngioma; Ependymoblastoma; Ependymoma; Medulloblastoma; Medulloepithelioma; Pineal Parenchymal Tumors of intermediate Differentiation; Supratentorial Primitive Neuroectodermal Tumors and Pineoblastoma; Visual Pathway and Hypothalamic Glioma; Brain and Spinal Cord Tumors; Breast Cancer; Bronchial Tumors; Burkitt Lymphoma; Carcinoid Tumor; Carcinoid Tumor, Gastrointestinal; Central Nervous System Atypical Teratoid / Rhabdoid Tumor; Central Nervous System Embryonal Tumors; Central Nervous System Lymphoma; Cerebellar Astrocytoma Cerebral Astrocytoma / Malignant Glioma, Childhood; Cervical Cancer; Chordoma, Childhood; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Chronic Myeloproliferative Disorders; Colon Cancer; Colorectal Cancer;Craniopharyngioma; Cutaneous T-Cell Lymphoma; Esophageal Cancer; Ewing Family of Tumors; Extragonadal Germ Cell Tumor; Extrahepatic Bile Duct Cancer; Eye Cancer, intraocular Melanoma; Eye Cancer, Retinoblastoma; Gallbladder Cancer; Gastric (Stomach) Cancer; Gastrointestinal Carcinoid Tumor; Gastrointestinal Stromal Tumor (GIST); Germ Cell Tumor, Extracranial; Germ Cell Tumor. Extragonadal; Germ CellTumor. Ovarian; Gestational Trophoblastic Tumor; Glioma; Glioma, Childhood Brain Stem; Glioma, Childhood Cerebral Astrocytoma; Glioma, Childhood Visual Pathway and Hypothalamic; Hairy' Cell Leukemia; Head and Neck Cancer; Hepatocellular (Liver) Cancer; Histiocytosis, Langerhans Cell; Hodgkin Lymphoma; Hypophary ngeal Cancer; Hypothalamic and Visual Pathway Glioma; intraocular Melanoma; Islet Cell Tumors; Kidney (Renal Cell) Cancer; Langerhans Cell Histiocytosis; Laryngeal Cancer; Leukemia. Acute Lymphoblastic; Leukemia, Acute Myeloid; Leukemia, Chronic Lymphocy tic; Leukemia, Chronic Myelogenous; Leukemia, Hairy7Cell; Lip and Oral Cavity7Cancer; Liver Cancer; Lung Cancer, Non-Small Cell; Lung Cancer, Small Cell; Lymphoma, AIDS- Related; Ly mphoma, Burkitt; Lymphoma. Cutaneous T-Cell; Lymphoma, Hodgkin; Lymphoma, Non-Hodgkin; Lymphoma, Primary Central Nervous System;Macroglobulinemia, Waldenstrom; Malignant Fibrous Histiocvtoma of Bone and Osteosarcoma; Medulloblastoma; Melanoma; Melanoma, intraocular (Eye); Merkel Cell Carcinoma; Mesothelioma; Metastatic Squamous Neck Cancer with Occult Primary; Mouth Cancer; Multiple Endocrine Neoplasia Syndrome, (Childhood); Multiple Myeloma / Plasma Cell Neoplasm; Mycosis; Fungoides; Myelodysplastic Syndromes; Myelodysplastic / Myeloproliferative Diseases; Myelogenous Leukemia, Chronic; Myeloid Leukemia, Adult Acute; Myeloid Leukemia, Childhood Acute; Myeloma, Multiple; Myeloproliferative Disorders, Chronic; Nasal Cavity and Paranasal Sinus Cancer; Nasopharyngeal Cancer; Neuroblastoma; Non-Small Cell Lung Cancer; Oral Cancer; Oral Cavity7Cancer; Orophary ngeal Cancer; Osteosarcoma and Malignant Fibrous Histiocytoma of Bone; Ovarian Cancer; Ovarian Epithelial Cancer; Ovarian Germ Cell Tumor; Ovarian Low Malignant Potential Tumor; Pancreatic Cancer; Pancreatic Cancer, Islet Cell Tumors; Papillomatosis; Parathyroid Cancer; Penile Cancer; Pharyngeal Cancer;Pheochromocytoma; Pineal Parenchymal Tumors of Intermediate Differentiation; Pineoblastoma and Supratentorial Primitive Neuroectodermal Tumors; Pituitary7Tumor; Plasma Celt Neoplasm / Multiple Myeloma; Pleuropulmonary Blastoma; Primary Central Nervous System Lymphoma; Prostate Cancer; Rectal Cancer; Renal Cell (Kidney) Cancer; Renal Pelvis and Ureter, Transitional Cell Cancer; Respiratory Tract Carcinoma Involving the NUT Gene on Chromosome 15; Retinoblastoma; Rhabdomyosarcoma; Salivary7Gland Cancer; Sarcoma, Ewing Family of Tumors; Sarcoma, Kaposi; Sarcoma, Soft Tissue; Sarcoma. Uterine; Sezary Syndrome; Skin Cancer (Nonmelanoma); Skin Cancer(Melanoma); Skin Carcinoma. Merkel Cell; Small Cell Lung Cancer; Small Intestine Cancer; Soft Tissue Sarcoma; Squamous Cell Carcinoma, Squamous Neck Cancer with Occult Primary', Metastatic; Stomach (Gastric) Cancer; Supratentorial Primitive Neuroectodermal Tumors; T-Cell Lymphoma, Cutaneous; Testicular Cancer; Throat Cancer; Thymoma and Thymic Carcinoma; Thyroid Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Trophoblastic Tumor, Gestational; Urethral Cancer; Uterine Cancer, Endometrial; Uterine Sarcoma; Vaginal Cancer; Vulvar Cancer; Waldenstrom Macroglobulinemia; and Wilms Tumor. In one embodiment, the cancer is associated with expression of IL13Ra2. In one embodiment, the cancer is glioblastoma.
[0177] In one embodiment, the invention provides a method to treat cancer metastasis comprising treating the subject prior to, concurrently with, or subsequently to the treatment with a composition of the invention, with a complementary7therapy for the cancer, such as surgery, chemotherapy, chemotherapeutic agent, radiation therapy, or hormonal therapy or a combination thereof.
[0178] Chemotherapeutic agents include cytotoxic agents (e.g., 5-fluorouracil, cisplatin, carboplatin, methotrexate, daunorubicin, doxorubicin, vincristine, vinblastine, oxorubicin, carmustine (BCNU), lomustine (CCNU), cytarabine USP, cyclophosphamide, estramucine phosphate sodium, altretamine, hydroxyurea, ifosfamide, procarbazine, mitomycin, busulfan, cyclophosphamide, mitoxantrone. carboplatin, cisplatin, interferon alfa-2a recombinant, paclitaxel, teniposide, and streptozoci), cytotoxic alkylating agents (e.g., busulfan, chlorambucil, cyclophosphamide, melphalan, or ethylesulfonic acid), alky lating agents (e.g., asaley, AZQ. BCNU, busulfan, bisulphan. carboxyphthalatoplatinum. CBDCA, CCNU, CHIP, chlorambucil, chlorozotocin, cisplatinum, clomesone, cyanomorpholinodoxorubicin, cyclodisone, cyclophosphamide, dianhydrogalactitol, fluorodopan, hepsulfam, hycanthone, iphosphamide, melphalan, methyl CCNU, mitomycin C, mitozolamide, nitrogen mustard, PCNU, piperazine, piperazinedione, pipobroman, porfiromycin. spirohydantoin mustard, streptozotocin, teroxirone, tetraplatin, thiotepa, triethylenemelamine, uracil nitrogen mustard, and Yoshi- 864), antimitotic agents (e.g., allocolchicine, Halichondrin M, colchicine, colchicine derivatives, dolastatin 10, may tansine, rhizoxin, paclitaxel derivatives, paclitaxel, thiocolchicine, trity l cysteine, vinblastine sulfate, and vincristine sulfate), plant alkaloids (e.g., actinomycin D. bleomycin, L-asparaginase, idarubicin, vinblastine sulfate, vincristinesulfate, mitramycin, mitomycin, daunorubicin, VP-16-213, VM-26. navelbine and taxotere), biologicals (e.g., alpha interferon, BCG, G-CSF, GM-CSF, and interleukin-2), topoisomerase I inhibitors (e.g., camptothecin, camptothecin derivatives, and morpholinodoxorubicin), topoisomerase II inhibitors (e.g., mitoxantron, amonafide, m- AMSA, anthrapyrazole derivatives, pyrazoloacridine, bisantrene HCL, daunorubicin, deoxydoxorubicin, menogaril. N,N-dibenzyl daunomycin, oxanthrazole, rubidazone. VM- 26 and VP- 16), and synthetics (e.g., hydroxyurea, procarbazine, o,p'-DDD, dacarbazine, CCNU, BCNU, cis-diamminedichloroplatimun, mitoxantrone, CBDCA, levamisole, hexamethylmelamine, all-trans retinoic acid, gliadel and porfimer sodium).
[0179] Antiproliferative agents are compounds that decrease the proliferation of cells. Antiproliferative agents include alkylating agents, antimetabolites, enzymes, biological response modifiers, miscellaneous agents, hormones and antagonists, androgen inhibitors (e.g.. flutamide and leuprolide acetate), antiestrogens (e.g., tamoxifen citrate and analogs thereof, toremifene, droloxifene and roloxifene), Additional examples of specific antiproliferative agents include, but are not limited to levamisole, gallium nitrate, granisetron, sargramostim strontium-89 chloride, filgrastim, pilocarpine, dexrazoxane, and ondansetron.
[0180] The compounds of the invention can be administered alone or in combination with other anti -tumor agents, including cytotoxic / antineoplastic agents and anti-angiogenic agents. Cytotoxic / anti -neoplastic agents are defined as agents which attack and kill cancer cells. Some cytotoxic / anti -neoplastic agents are alkylating agents, which alky late the genetic material in tumor cells, e.g., cis-platin, cyclophosphamide, nitrogen mustard, trimethylene thiophosphoramide, carmustine, busulfan, chlorambucil, belustine, uracil mustard, chlomaphazin, and dacabazine. Other cytotoxic / anti-neoplastic agents are antimetabolites for tumor cells, e.g., cytosine arabinoside, fluorouracil, methotrexate, mercaptopuirine, azathioprime, and procarbazine. Other cytotoxic / anti-neoplastic agents are antibiotics, e.g., doxorubicin, bleomycin, dactinomycin, daunorubicin, mithramycin, mitomycin, mytomycin C, and daunomycin. There are numerous liposomal formulations commercially available for these compounds. Still other cytotoxic / anti-neoplastic agents are mitotic inhibitors (vinca alkaloids). These include vincristine, vinblastine and etoposide. Miscellaneous cytotoxic / anti-neoplastic agents include taxol and its derivatives, L-asparaginase, anti-tumor antibodies, dacarbazine, azacytidine, amsacrine. melphalan. VM- 26, ifosfamide, mitoxantrone, and vindesine.
[0181] Anti-angiogenic agents are well known to those of skill in the art. Suitable anti-angiogenic agents for use in the methods and compositions of the invention include anti-VEGF antibodies, including humanized and chimeric antibodies. anti-VEGF aptamers and antisense oligonucleotides. Other known inhibitors of angiogenesis include angiostatin, endostatin, interferons, interleukin 1 (including alpha and beta) interleukin 12, retinoic acid, and tissue inhibitors of metalloproteinase- 1 and -2. (TIMP-1 and -2). Small molecules, including topoisomerases such as razoxane, a topoisomerase II inhibitor with anti- angiogenic activity, can also be used.
[0182] Other anti-cancer agents that can be used in combination with the compositions of the invention include, but are not limited to: acivicin; aclarubicin; acodazole hydrochloride; acronine; adozelesin; aldesleukin; altretamine; ambomycin; ametantrone acetate; aminoglutethimide; amsacrine; anastrozole; anthramycin; asparaginase; asperlin; azacitidine; azetepa; azotomycin; batimastat; benzodepa; bicalutamide; bisantrene hydrochloride; bisnafide dimesylate; bizelesin; bleomycin sulfate; brequinar sodium; bropirimine; busulfan; cactinomycin; calusterone; caracemide; carbetimer; carboplatin; carmustine; carubicin hydrochloride; carzelesin; cedefingol; chlorambucil; cirolemycin; cisplatin; cladribine: crisnatol mesylate; cyclophosphamide; cytarabine; dacarbazine; dactinomycin; daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine; dezaguanine mesylate; diaziquone; docetaxel; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; dromostanolone propionate; duazomycin; edatrexate; eflomithine hydrochloride: elsamitrucin; enloplatin; enpromate; epipropidine; epirubicin hydrochloride; erbulozole; esorubicin hydrochloride; estramustine; estramustine phosphate sodium; etanidazole; etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; fluorocitabine; fosquidone; fostriecin sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; ilmofosine; interleukin II (including recombinant interleukin II, or rIL2), interferon alfa-2a; interferon alfa-2b; interferon alfa-nl; interferon alfa-n3; interferon beta-I a; interferon gamma-I b; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate: liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprocol;maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menogaril; mercaptopurine; methotrexate; methotrexate sodium; metoprine; meturedepa; mitindomide; mitocarcin; mitocromin; mitogillin; mitomalcin; mitomycin; mitosper; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazole; nogalamycin; ormaplatin; oxisuran; paclitaxel; pegaspargase; peliomycin; pentamustine; peplomycin sulfate; perfosfamide; pipobroman; piposulfan; piroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; porfiromycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin; riboprine; rogletimide; safingol; safingol hydrochloride; semustine; simtrazene; sparfosate sodium; sparsomycin; spirogermanium hydrochloride; spiromustine; spiroplatin; streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan sodium; tegafur; teloxantrone hydrochloride; temoporfm; teniposide; teroxirone; testolactone; thiamiprine; thioguanine; thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone acetate; triciribine phosphate; trimetrexate; trimetrexate glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard; uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine sulfate; vindesine; vindesine sulfate; vinepidine sulfate; vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate; vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin; zinostatin; zorubicin hydrochloride. Other anti-cancer drugs include, but are not limited to: 20-epi-l,25 dihydroxy vitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti- dorsalizing morphogenetic protein- 1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR / ABL antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives; beta-al ethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilagederived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorins; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin; dexamethasone; dexifosfamide; dexrazoxane; dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; dihydrotaxol, 9-; dioxamycin; diphenyl spiromustine; docetaxel; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflomithine; elemene; emitefur; epirubicin; epristeride; estramustine analogue; estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; fdgrastim; finasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-like growth factor-1 receptor inhibitor; interferon agonists; interferons; interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine; mannostatin A; marimastat; masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim; mismatched double stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A+myobacterium cellwall sk; mopidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1- based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip; naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide antioxidant; mtrullyn; O6-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; paclitaxel; paclitaxel analogues; paclitaxel derivatives; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin; pentrozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine complex; porfimer sodium; porfiromycim prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylene conjugate; raf antagonists; raltitrexed; ramosetron; ras famesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide; rogletimide; rohitukine; romurtide; roquinimex; rubiginone Bl; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen binding protein; sizofuran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfinosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfin; temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine; thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptoragonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene bichloride; topsentin; toremifene; totipotent stem cell factor; translation inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron; turosteride; ty rosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol; veramine; verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; and zinostatin stimalamer. In one embodiment, the anti-cancer drug is 5-fluorouracil, taxol, or leucovorin.Examples
[0183] The present invention is further illustrated in the following Examples. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, various modifications of the invention in addition to those shown and described herein will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.Example 1 : A single administration of DNA-encoded tri-specific T cell engager (DTriTE) targeting EGFRvIII, IL13Ra2, and CD3 shows complete tumor clearance in an orthotopic challenge model of heterogeneous GBM
[0184] Glioblastoma multiforme (GBM) is the most common and lethal form of primary- brain tumors in adults with a five-year survival rate less than 5%. In recent years, immunotherapeutic approaches that target a tumor-associated antigen (TAA), including EGFRvIII-targeted cancer vaccine and adoptive cell transfer, have been examined in clinical studies, which so far have show n limited efficacy in GBM patients. GBM is highly heterogeneous for targeting antigen expression. An immunotherapeutic agent that harnesses multiple TAAs simultaneously may mitigate tumor antigen escape and improve efficacy in GBM patients.
[0185] The results presented herein describe a DNA-encoded tri-specific T cell engager (DTriTE) that targets CD3 and two TAAs, EGFRvIII and IL13Ra2, which are expressed in up to 30% and 75% of GBM cases, respectively. The EGFRvIII-IL13Ra2- DTriTE construct was designed to include single-chain variable fragments targeting IL13Ra2. CD3, and EGFRvIII in a series, fused with glycine-serine linkers. EGFRvIII- IL13Ra2-DTriTE exhibited robust binding activities to both EGFRvlIH- and IL13Ra2+ tumor cells and primary T cells, inducing robust T cell activation and anti-tumor cytotoxicity. EGFRvIII-IL13Ra2-DTriTE showed durable in vivo expression of over 10 weeks after a single IM injection in NSG mice.
[0186] Experiments were designed to developed an orthotopic challenge of a heterogeneous GBM model, wherein a mixture of EGFRvIII+ tumor cells and IL13Ra2+ tumor cells were planted in the brains of NSG mice and primary human T cells were peripherally delivered. A single IM administration of EGFRvIII-IL13Ra2 -DTriTE resulted in complete tumor clearance. An administration of DNA-encoded bispecific T cell engager (DBTE) targeting EGFRvIII alone induced tumor clearance in 3 of 10 (30%) and limited tumor control in 5 of 10 (50%) animals. Similarly, mono-targeting of IL13Ra2 alone induced tumor clearance in 1 of 9 (1 1%) and limited tumor control in 4 of 9 (44%) animals. EGFRvIII-IL13Ra2-DTriTE treatment exhibited significantly improved survival with 8 of 8 (100%) animals survived, while treatments of single EGFRvIII -DBTE, IL13Ra2-DBTE or a vehicle control resulted in 4 of 10 (40%), 4 of 9 (44%), and 0 of 10 (0%) animals survived, respectively. This study shows that dual tumor-targeting approach using DTriTE is highly effective at treating antigenically heterogeneous GBM tumors. Further study of DTriTE multi-antigen approaches for GBM and other heterogeneous tumors appears important.Example 2: DTriTE promotes T cell mediated cvtotoxicitv
[0187] A DTriTE construct was designed to target IL13Ra2, EGFRvIII, and CD3 and validated for in vivo expression (Figure 1). Flow cytometry was performed to confirm that DTriTE showsin on cell binding activities to EGFRvIII-, IL13Ra2-, and CD3- expressing cells (Figure 2). pVAX and a FSHR-targeting DBTE were used as controls.
[0188] After showing that the DTriTE binds to its targets. T cell-mediated cytotocisity of the DTriTE against EGFRvIII and IL13Ra2-expressing GBM cells was assessed (Figure 3). DTriTE demonstrated long-term expression after a single treatment (Figure 4).
[0189] The DTriTE demonstrated the ability7to clear heterogeneous tumors in mice given an orthotopic GBM challenge (Figure 5). In sum, the EGFRvIII, IL13Ra2, CD3 DTriTE was shown to be specific, have long term expression, and mediates tumor cell clearing.Example 3: SequencesDTriTE 1 (IL13Ra2xCD3xEGFRvIII);DNA sequence: SEQ ID NO: 1ATGGATTGGACCTGGATCCTGTTCCTGGTGGCCGCTGCCACCAGGGTGCACAGC GATATCCAGATGACACAGTCCCCTAGCTCCCTGAGCGCCTCCGTGGGCGACAG GGTGACCATCACATGCACCGCCTCTCTGAGCGTGTCTAGCACATACCTGCACTG GTACCAGCAGAAGCCAGGCTCCTCTCCCAAGCTGTGGATCTACTCCACCTCTAA CCTGGCTTCCGGCGTGCCATCTAGGTTCAGCGGCTCCGGATCTGGCACATCTTA CACACTGACCATCAGCTCCCTGCAGCCTGAGGACTTCGCCACCTACTACTGCCA CCAGTACCACCGGTCCCCACTGACATTTGGCGGAGGCACCAAGGTGGAGATCA AGGGAGGCGGAGGCAGCGGAGGCGGAGGCTCCGGAGGCGGAGGCTCTGAGGT GCAGCTGGTGGAGAGCGGAGGCGGACTGGTGCAGCCTGGCGGAAGCCTGAGA CTGTCCTGTGCTGCCTCTGGATTCAGCCTGACCAAGTACGGAGTGCACTGGGTG CGGCAGGCTCCAGGAAAGGGACTGGAGTGGGTGGGAGTGAAGTGGGCTGGCG GATCCACCGATTACAACTCTGCCCTGATGAGCAGGTTCACCATCTCTAAGGACA ACGCCAAGAACAGCCTGTACCTGCAGATGAACTCCCTGCGGGCTGAGGATACC GCC GTGTACTACTGC GCTAGGGAC C AC AGAGATGC C ATGGACTACTGGGGAC A GGGCACACTGGTGACCGTGTCTAGCGGCGGAGGCGGATCCGAAGTCCAGCTCG TGGAGAGCGGCGGAGGCCTGGTGCAGCCAGGAGGCTCCCTGAGGCTGTCTTGT GCTGCCTCCGGATACTCTTTCACAGGCTACACCATGAACTGGGTGAGGCAGGCC CCTGGAAAGGGCCTGGAGTGGGTGGCCCTGATCAACCCCTACAAGGGCGTGAG CACATACAACCAGAAGTTCAAGGATAGGTTCACCATCAGCGTGGACAAGTCCA AGAACACAGCTTACCTGCAAATGAACTCCCTGCGCGCCGAAGACACAGCCGTG TACTACTGCGCCAGGTCCGGATACTACGGCGACTCTGATTGGTACTTTGACGTG TGGGGCCAGGGCACACTGGTCACCGTGTCCTCTGGAGGCGGAGGCAGCGGAGG CGGAGGCTCCGGAGGCGGAGGCAGCGACATCCAGATGACACAGAGCCCATCTTCTCTCAGCGCCTCTGTGGGCGATAGGGTGACAATCACCTGTCGCGCCTCCCAGG ACATCAGGAACTACCTGAATTGGTATCAGCAGAAGCCTGGCAAGGCCCCAAAG CTGCTGATCTACTACACCTCTAGACTGGAGAGCGGAGTGCCATCCCGGTTCTCT GGAAGCGGATCCGGAACAGATTACACACTGACCATCTCTAGCCTGCAGCCCGA AGATTTTGCTACCTACTACTGCCAGCAGGGCAACACACTGCCTTGGACCTTTGGCCAGGGAACAAAAGTCGAGATCAAGGGAGGCGGAGGCTCTGACGTGGTCATGACACAGAGCCCAGACTCCCTGGCCGTGAGCCTGGGAGAGCGGGCCACCATCAACTGTAAGTCCTCTCAGTCTCTGCTGGACAGCGATGGCAAGACATACCTGAACTGGCTGCAGCAGAAGCCAGGACAGCCCCCTAAGCGCCTGATCTCTCTGGTGAGCAAGCTGGATAGCGGAGTGCCAGACAGGTTCTCTGGCTCTGGATCCGGCACCGACTTCACCCTCACAATCAGCTCCCTGCAGGCTGAGGACGTGGCCGTGTACTACTGCTGGCAGGGAACACACTTCCCTGGCACCTTTGGAGGCGGAACAAAGGTGGAGATCAAGGGCGGAGGCGGAAGCGGCGGAGGCGGATCCGGCGGAGGCGGATCTGGCGGAGGCGGAAGCGAGATCCAGCTGGTGCAGTCCGGAGCCGAGGTGAAGAAGCCCGGCGAGTCCCTGCGCATCTCTTGTAAGGGAAGCGGCTTCAACATCGAGGACTACTACATCCACTGGGTGAGACAGATGCCAGGAAAGGGTCTGGAGTGGATGGGCCGGATCGATCCCGAGAACGACGAGACCAAGTACGGACCTATCTTCCAGGGCCACGTGACAATCTCCGCTGATACATCTATCAACACCGTGTACCTGCAGTGGTCTAGCCTGAAGGCTAGCGACACAGCCATGTACTACTGTGCCTTTAGGGGCGGAGTGTACTGGGGACAGGGCACCACAGTGACCGTGTCCTCTTGAmino acid sequence (IL13Ra2xCD3xEGFRvIII): SEQ ID NO: 2MDWTWILFLVAAATRVHSDIQMTQSPSSLSASVGDRVTITCTASLSVSSTYLHWYQ QKPGSSPKLWIYSTSNLASGVPSRFSGSGSGTSYTLTISSLQPEDFATYYCHQYHRSP LTFGGGTKVEIKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFS LTKYGVHWVRQAPGKGLEWVGVKWAGGSTDYNSALMSRFTISKDNAKNSLYLQ MNSLRAEDTAVYYCARDHRDAMDYWGQGTLVTVSSGGGGSEVQLVESGGGLVQ PGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDR FTISVDKSKNTAYLQMNSLRAEDTAVYYCARSGYYGDSDWYFDVWGQGTLVTVS SGGGGSGGGGSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQDIRNYLNWYQQK PGKAPKLLIYYTSRLES GVP SRFSGSGS GTDYTLTIS SLQPEDF ATYYCQQGNTLP W TFGQGTKVEIKGGGGSDVVMTQSPDSLAVSLGERATINCKSSQSLLDSDGKTYLN WLQQKPGQPPKRLISLVSKLDSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCWQ GTHFPGTFGGGTKVEIKGGGGSGGGGSGGGGSGGGGSEIQLVQSGAEVKKPGESL RISCKGSGFNIEDYYIHWVRQMPGKGLEWMGRIDPENDETKYGPIFQGHVTISADT SINTVYLQWSSLKASDTAMYYCAFRGGVYWGQGTTVTVSSDTi iTE 2 (CD3xEGFRvIIIxIL13Ra2):DNA sequence: SEQ ID NO: 3ATGGATTGGACCTGGATACTGTTCCTGGTGGCCGCCGCCACCAGAGTGCACAG CGAGGTGCAGCTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCTGGCGGCTCTC TGCGCCTGAGCTGCGCCGCCTCTGGCTATAGCTTTACCGGCTACACCATGAACT GGGTGCGCCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGCCCTGATCAATCCC TACAAGGGCGTGAGCACATACAACCAGAAGTTTAAGGATCGGTTCACAATCAG CGTGGATAAGTCTAAGAACACCGCCTATCTGCAGATGAACAGCCTGAGAGCCG AGGATACCGCCGTGTATTATTGTGCCAGATCTGGCTATTACGGCGACTCCGATT GGTACTTCGACGTGTGGGGCCAGGGCACCCTGGTGACAGTGTCTTCCGGCGGCGGCGGCAGCGGCGGCGGCGGCAGCGGCGGCGGCGGCTCTGACATCCAGATGACCCAGTCTCCTTCTAGCCTGTCCGCCTCTGTGGGCGATCGCGTGACAATCACCTGCCGGGCCTCTCAGGATATCAGGAACTACCTGAATTGGTACCAGCAGAAGCCCGGCAAGGCCCCAAAGCTGCTGATCTACTATACCAGCAGACTGGAGTCTGGCGTGCCATCTCGCTTCTCTGGCAGCGGCTCTGGCACCGATTACACCCTGACCATCTCTTCTCTGCAGCCTGAGGATTTCGCCACATACTATTGTCAGCAGGGCAATACACTGCCCTGGACCTTTGGCCAGGGCACAAAGGTGGAGATCAAGGGCGGCGGCGGCTCCGACGTGGTAATGACCCAGTCTCCCGATTCCCTGGCCGTGAGCCTGGGCGAGAGAGCCACAATCAACTGCAAGTCTAGCCAGAGCCTGCTGGATAGCGATGGCAAGACATACCTGAACTGGCTGCAGCAGAAGCCAGGCCAGCCACCTAAGCGGCTGATCAGCCTGGTGTCCAAGCTGGACTCCGGCGTGCCCGATAGATTCAGCGGCTCCGGCTCCGGCACCGATTTCACACTGACCATCTCTAGCCTGCAGGCCGAGGACGTGGCCGTGTACTACTGTTGGCAGGGCACCCACTTCCCCGGCACCTTTGGCGGCGGCACAAAGGTGGAGATCAAGGGCGGCGGCGGCTCCGGCGGCGGCGGCTCTGGCGGCGGCGGCAGCGGCGGCGGCGGCAGCGAGATCCAGCTGGTGCAGAGCGGCGCCGAGGTGAAGAAGCCCGGCGAGAGCCTGAGGATCAGCTGCAAGGGCTCTGGCTTCAACATCGAGGATTATTACATCCACTGGGTGCGCCAGATGCCTGGCAAGGGCCTGGAGTGGATGGGCAGGATCGATCCCGAGAACGATGAGACCAAGTACGGCCCTATCTTTCAGGGCCACGTGACAATCAGCGCCGATACCTCTATCAATACCGTGTACCTGCAGTGGTCCAGCCTGAAGGCCTCTGATACAGCCATGTACTATTGCGCCTTTAGAGGCGGCGTGTACTGGGGCCAGGGCACAACCGTGACAGTGTCCTCTGGCGGCGGCGGCAGCGACATCCAGATGACCCAGTCTCCAAGCTCCCTGAGCGCCAGCGTGGGCGACAGAGTGACAATCACCTGTACAGCCTCCCTGTCTGTATCTTCCACCTATCTGCACTGGTATCAGCAGAAGCCTGGCAGCAGCCCAAAGCTGTGGATCTACAGCACAAGCAACCTGGCCTCCGGCGTGCCAAGCCGGTTCTCTGGCTCCGGCTCTGGCACAAGCTATACACTGACCATCAGCTCCCTGCAGCCCGAGGATTTTGCCACCTATTATTGCCACCAGTACCACAGGAGCCCCCTGACATTTGGCGGCGGCACCAAGGTGGAGATCAAGGGCGGCGGCGGCTCTGGCGGCGGCGGCTCCGGCGGCGGCGGCTCTGAGGTGCAGCTGGTGGAGTCCGGCGGCGGCCTGGTGCAGCCCGGCGGCAGCCTGAGACTGTCTTGCGCCGCCAGCGGCTTTAGCCTGACAAAGTATGGCGTGCACTGGGTGCGGCAGGCCCCAGGCAAGGGCCTGGAGTGGGTGGGCGTGAAGTGGGCCGGCGGCTCCACCGATTATAACTCCGCCCTGATGTCTCGGTTTACCATCTCCAAGGACAATGCCAAGAACTCCCTGTACCTGCAGATGAACTCCCTGAGGGCCGAGGATACAGCCGTGTACTATTGTGCCCGCGATCACCGCGACGCCATGGATTATTGGGGCCAGGGCACCCTGGTGACAGTGAGCTCCAmino acid sequence: SEQ ID NO: 4MDWTWILFLVAAATRVHSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNW VRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDT AVYYCARSGYYGDSDWYFDVWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQS PSSLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSG SGSGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIKGGGGSDVVMTQSP DSLAVSLGERATINCKSSQSLLDSDGKTYLNWLQQKPGQPPKRLISLVSKLDSGVP DRFSGSGSGTDFTLTISSLQAEDVAVYYCWQGTHFPGTFGGGTKVEIKGGGGSGGG GSGGGGSGGGGSEIQLVQSGAEVKKPGESLRISCKGSGFNIEDYYIHWVRQMPGKG LEWMGRIDPENDETKYGPIFQGHVTISADTSINTVYLQWSSLKASDTAMYYCAFRG GVYWGQGTTVTVSSGGGGSDIQMTQSPSSLSASVGDRVTITCTASLSVSSTYLHWYQQKPGSSPKLWIYSTSNLASGVPSRFSGSGSGTSYTLTISSLQPEDFATYYCHQYHRSPLTFGGGTKVEIKGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFSLTKYGVHWVRQAPGKGLEWVGVKWAGGSTDYNSALMSRFTISKDNAKNSLYLQMNSLRAEDTAVYYCARDHRDAMDYWGQGTLVTVSSDTriTE 3 (EGFRvIIIxIL13Ra2xCD3):DNA sequence: SEQ ID NO: 5ATGGACTGGACCTGGATACTGTTCCTGGTGGCCGCCGCCACAAGGGTGCACTCC GACGTGGTAATGACCCAGAGCCCAGATAGCCTGGCCGTGTCTCTGGGCGAGAG GGCCACCATCAACTGCAAGAGCTCTCAGAGCCTGCTGGATAGCGATGGCAAGA CCTATCTGAACTGGCTGCAGCAGAAGCCCGGCCAGCCACCTAAGCGCCTGATC AGCCTGGTGTCTAAGCTGGATAGCGGCGTGCCAGACCGGTTCTCCGGCTCTGGC TCTGGCACCGATTTCACACTGACAATCTCTTCCCTGCAGGCCGAGGATGTGGCC GTGTACTATTGTTGGCAGGGCACCCACTTTCCAGGCACATTTGGCGGCGGCACC AAGGTGGAGATCAAGGGCGGCGGCTCCGGCGGCGGCGGCTCCGGCGGCGGCG GCTCCGGCGGCGGCGGCTCTGAGATCCAGCTGGTGCAGTCCGGCGCCGAGGTG AAGAAGCCTGGCGAGTCCCTGCGGATCTCTTGTAAGGGCAGCGGCTTCAATAT CGAGGACTACTACATCCACTGGGTGCGGCAGATGCCTGGCAAGGGCCTGGAGT GGATGGGCAGGATCGATCCCGAGAATGATGAGACAAAGTACGGCCCAATCTTC CAGGGCCACGTGACAATCTCTGCCGATACCTCCATCAACACCGTGTACCTGCAG TGGAGCTCTCTGAAGGCCTCTGATACCGCCATGTACTATTGCGCCTTCCGCGGC GGCGTGTATTGGGGCCAGGGCACCACCGTGACAGTGTCTTCTGGCGGCGGCGG CTCTGATATCCAGATGACCCAGTCTCCTTCTTCCCTGTCTGCCAGCGTGGGCGA TAGGGTGACAATCACCTGCACAGCCAGCCTGTCTGTGAGCTCCACATACCTGCA CTGGTACCAGCAGAAGCCAGGCAGCTCTCCAAAGCTGTGGATCTACTCTACCTC CAATCTGGCCTCTGGCGTGCCCAGCCGCTTTTCCGGCTCTGGCTCCGGCACCAG CTACACCCTGACAATCAGCTCCCTGCAGCCAGAGGACTTCGCCACCTACTATTG CCACCAGTACCACCGGTCTCCTCTGACCTTCGGCGGCGGCACAAAGGTGGAGA TCAAGGGCGGCGGCGGCAGCGGCGGCGGCGGCTCTGGCGGCGGCGGCGGCTCC GAGGTGCAGCTGGTGGAGTCCGGCGGCGGCCTGGTGCAGCCAGGCGGCAGCCT GCGCCTGTCTTGCGCCGCCTCTGGCTTTAGCCTGACCAAGTACGGCGTGCACTG GGTGCGCCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGGCGTGAAGTGGGCCG GCGGCAGCACCGATTACAATTCCGCCCTGATGAGCAGATTCACCATCAGCAAG GACAATGCCAAGAACTCCCTGTACCTGCAGATGAATTCTCTGAGGGCCGAGGA TACCGCCGTGTATTACTGCGCCAGGGATCACCGGGATGCCATGGACTACTGGG GCCAGGGCACACTGGTGACCGTGTCCTCCGGCGGCGGCGGCAGCGAGGTGCAG CTGGTGGAGAGCGGCGGCGGCCTGGTGCAGCCTGGCGGCTCTCTGAGGCTGAG CTGTGCCGCCTCCGGCTACAGCTTTACAGGCTATACCATGAACTGGGTGAGACA GGCCCCAGGCAAGGGCCTGGAGTGGGTGGCCCTGATCAATCCCTATAAGGGCG TGTCTACCTATAACCAGAAGTTCAAGGATAGGTTTACAATCAGCGTGGACAAG TCCAAGAACACCGCCTATCTGCAGATGAACTCCCTGCGGGCCGAGGATACAGCCGTGTACTATTGCGCCAGGTCCGGCTATTACGGCGATAGCGATTGGTACTTCGA CGTGTGGGGCCAGGGCACCCTGGTGACAGTGTCCAGCGGCGGCGGCGGCTCTG GCGGCGGCGGCAGCGGCGGCGGCGGCAGCGATATCCAGATGACCCAGTCCCCT AGCAGCCTGTCCGCCTCTGTGGGCGACAGAGTGACCATCACATGCCGGGCCTCT CAGGACATCCGCAACTACCTGAATTGGTATCAGCAGAAGCCCGGCAAGGCCCCCAAGCTGCTGATCTACTATACAAGCCGCCTGGAGAGCGGCGTGCCTTCTAGGTTTTCCGGCAGCGGCTCCGGCACAGACTATACACTGACCATCAGCTCCCTGCAGCCTGAGGATTTCGCCACATACTACTGTCAGCAGGGCAATACCCTGCCATGGACATTCGGCCAGGGCACAAAGGTGGAGATCAAGAmino acid sequence: SEQ ID NO: 6MDWTWILFLVAAATRVHSDVVMTQSPDSLAVSLGERATINCKSSQSLLDSDGKTY LNWLQQKPGQPPKRLISLVSKLDSGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCWQGTHFPGTFGGGTKVEIKGGGSGGGGSGGGGSGGGGSEIQLVQSGAEVKKPGES LRISCKGSGFNIEDYYIHWVRQMPGKGLEWMGRIDPENDETKYGPIFQGHVTISAD TSINTVYLQWSSLKASDTAMYYCAFRGGVYWGQGTTVTVSSGGGGSDIQMTQSPS SLSASVGDRVTITCTASLSVSSTYLHWYQQKPGSSPKLWIYSTSNLASGVPSRFSGS GSGTSYTLTISSLQPEDFATYYCHQYHRSPLTFGGGTKVEIKGGGGSGGGGSGGGG GSEVQLVESGGGLVQPGGSLRLSCAASGFSLTKYGVHWVRQAPGKGLEWVGVK WAGGSTDYNSALMSRFTISKDNAKNSLYLQMNSLRAEDTAVYYCARDHRDAMD YWGQGTLVTVSSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGYSFTGYTMNWVRQAPGKGLEWVALINPYKGVSTYNQKFKDRFTISVDKSKNTAYLQMNSLRAEDTA VYYCARSGYYGDSDWYFDVWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPS SLSASVGDRVTITCRASQDIRNYLNWYQQKPGKAPKLLIYYTSRLESGVPSRFSGSG SGTDYTLTISSLQPEDFATYYCQQGNTLPWTFGQGTKVEIKSEQ ID N0:7 - IgE leaderMDWTWILFLVAAATRVHS
[0190] It is understood that the foregoing detailed description and accompanying examples are merely illustrative and are not to be taken as limitations upon the scope of the invention, which is defined solely by the appended claims and their equivalents.
[0191] Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art. Such changes and modifications, including without limitation those relating to the chemical structures, substituents, derivatives, intermediates, syntheses, compositions, formulations, or methods of use of the invention, may be made without departing from the spirit and scope thereof.
Claims
CLAIMSWhat is claimed is:
1. A synthetic trispecific T cell engager (TriTE), wherein the synthetic trispecific immune cell engager comprises three binding domains, wherein at least one binding domain is a disease-associated antigen binding domain and at least one binding domain immune cell engaging domain.
2. The TriTE of claim 1, wherein the TriTE comprises two disease-associated antigen binding domains.
3. The TriTE of claim 2, wherein at least one disease-associated antigen binding domains is specific for binding a tumor antigen.
4. The TriTE of claim 3, wherein the tumor antigen is EGFRvIII or IL13Ra2.
5. The TriTE of claim 2, wherein at least one antigen binding domain targets EGFRvIII, and further wherein at least one antigen binding domain targets IL13Ra2.
6. The TriTE of claim 1, wherein the immune cell engaging domain targets at least one T cell specific receptor molecule selected from the group consisting of CD3, the T cell receptor (TCR), CD28, CD16. NKG2D. 0x40, 4-1BB, CD2, CD5, CD40, FcgRs, FceRs, FcaRs and CD957. The TriTE of claim 6, wherein the immune cell engaging domain targets CD3.
8. The TriTE of claim 1, wherein the TriTE comprises two antigen binding domains and one immune cell engaging domain.
9. The TriTE of claim 8, wherein the TriTE comprises an antigen binding domain that targets EGFRvIII, an antigen binding domain that targets IL13Ra2, and an immune cell engaging domain that targets CD3.
10. The TriTE of claim 1 comprising one or more sequences selected from the group consisting of: a) an amino acid sequence having at least about 90% identity over an entire length of the amino acid sequence to SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6, wherein the variation is outside of the CDR sequences of SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO: 6; b) a fragment of an amino acid sequence having at least about 90% identity over at least 65% of SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6, wherein the fragment comprises at least the CDR sequences of SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO:6; and c) an amino acid sequence of SEQ ID NO:2, SEQ ID NO:4 or SEQ ID NO: 6.
11. The TriTE of claim 10, wherein the fragment comprises a fragment of SEQ ID NO:
2. SEQ ID NO:4 or SEQ ID NO:6 lacking the IgE leader sequence.
12. A nucleic acid molecule encoding a TriTE of any one of claims 1-11.
13. The nucleic acid molecule of claim 12. wherein the nucleic acid molecule is selected from the group consisting of an RNA molecule and a DNA molecule.
14. The nucleic acid molecule of claim 12 or claim 13, comprising a nucleotide sequence selected from the group consisting of: a) a nucleotide sequence having at least about 90% identity over an entire length of the nucleic acid sequence to SEQ ID NO: 1, SEQ ID NO:3 or SEQ ID NO:5, wherein the variation is outside of the CDR coding sequences of SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5;b) a fragment of a nucleotide sequence having at least about 90% identity over at least 65% of the nucleic acid sequence to SEQ ID NO: 1, SEQ ID NO: 3 or SEQ ID NO: 5, wherein the fragment comprises at lest the CDR coding sequences of SEQ ID NO: 1 SEQ ID NO:3 or SEQ ID NO:5; and c) a nucleotide sequence of SEQ ID NO: 1, SEQ ID NO:3 or SEQ ID NO:5.
15. The nucleic acid molecule of any one of claims 12-14, wherein the nucleic acid molecule comprises an expression vector.
16. A composition comprising the TriTE of any one of claims 1-11 or the nucleic acid molecule of any one of claims 12-15.
17. The composition of claim 16, further comprising a pharmaceutically acceptable excipient, an adjuvant, or a combination thereof.
18. The composition of claim 16, comprising a delivery vehicle comprising or encapsulating the nucleic acid molecule of any one of claims 12-15.
19. The composition of claim 18, wherein the delivery vehicle is a lipid nanoparticle.
20. A method of preventing or treating cancer in a subject, the method comprising administering to the subject the TriTE of any one of claims 1-11, the nucleic acid molecule of any one of claims 12-15 or the composition of any one of claims 16-19.
21. The method of claim 20, wherein the cancer is glioblastoma multiforme.
Citation Information
Patent Citations
Chimeric antigen receptor t cells targeting the tumor microenvironment
US20200113940A1
DNA-encoded bispecific antibodies targeting il13rα2 and methods of use in cancer therapeutics
WO2022198027A1
